Arrowstreet Capital Limited Partnership lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 60.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,004,689 shares of the company’s stock after selling 1,504,237 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Johnson & Johnson were worth $245,586,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently modified their holdings of the company. Sierra Capital LLC raised its stake in shares of Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after buying an additional 41 shares during the last quarter. Beaird Harris Wealth Management LLC grew its holdings in Johnson & Johnson by 1.8% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after acquiring an additional 42 shares during the period. Broadleaf Partners LLC boosted its position in shares of Johnson & Johnson by 0.6% in the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock worth $1,521,000 after purchasing an additional 43 shares during the last quarter. Jessup Wealth Management Inc grew its stake in shares of Johnson & Johnson by 0.6% during the fourth quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock worth $1,567,000 after purchasing an additional 44 shares during the period. Finally, Plancorp LLC grew its stake in shares of Johnson & Johnson by 0.3% during the fourth quarter. Plancorp LLC now owns 15,889 shares of the company’s stock worth $3,288,000 after purchasing an additional 45 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades Several equities analysts have weighed in on JNJ shares. TD Cowen increased their target price on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Johnson Rice upgraded shares of Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 price target on the stock in a research report on Thursday, July 16th. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Guggenheim reaffirmed a “buy” rating and issued a $270.00 target price on shares of Johnson & Johnson in a research note on Friday, July 17th. Finally, Argus increased their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $265.30.
Read Our Latest Stock Report on JNJ
Johnson & Johnson Stock Performance Shares of JNJ stock opened at $263.43 on Friday. Johnson & Johnson has a 12 month low of $164.23 and a 12 month high of $269.43. The company’s fifty day simple moving average is $242.71 and its 200-day simple moving average is $236.32. The firm has a market cap of $634.13 billion, a PE ratio of 30.52, a P/E/G ratio of 2.46 and a beta of 0.24. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter last year, the firm earned $2.77 earnings per share. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts expect that Johnson & Johnson will post 11.68 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.
Insider Buying and Selling In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.
Johnson & Johnson News Summary Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Analysts highlighted that JNJ raised its outlook, with guidance upgrades adding to investor confidence after the company’s recent earnings beat. Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher Positive Sentiment: JNJ’s Innovative Medicine unit reported strong Q2 growth, helping show resilience even after Stelara patent loss and suggesting momentum can continue into the second half of 2026. J&J’s Innovative Medicine Unit Proves Its Resilience in Q2 Positive Sentiment: Positive topline Phase 3 data for TECVAYLI and TALVEY showed large reductions in disease progression and death risk in relapsed/refractory multiple myeloma, strengthening JNJ’s oncology pipeline. TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma Positive Sentiment: JNJ also received FDA De Novo authorization for its OTTAVA robotic surgical system, expanding its competitiveness in soft-tissue robotic surgery and broadening a potentially important growth platform. Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors? Neutral Sentiment: Several articles framed JNJ as a defensive dividend stock and a steady healthcare holding, which reinforces its safe-haven appeal but is less likely to move the shares on its own. 3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives Neutral Sentiment: Commentary on JNJ’s steadiness during market volatility and ETF exposure after earnings mainly reflects investor interest in the stock rather than a new fundamental change. ETFs to Buy Post JNJ’s Q2 Earnings Beat & Bullish 2026 Outlook Johnson & Johnson Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Stories Five stocks we like better than Johnson & Johnson AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEArrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Affinity Asset Advisors LLC
NEXT HEADLINE »Aristotle Capital Management LLC Acquires Shares of 2,266,047 Motorola Solutions, Inc. $MSI
It would be easy to not notice. The company isn't exactly disrupting the pharmaceutical business, after all. In fact, most investors would struggle to name a single drug the company makes.
Just dig deeper. Last quarter's results may be a glimpse of the growth that Johnson & Johnson (JNJ +1.56%) quietly has in store for patient investors.
Image source: Getty Images.
Cancer drugs to lead growth You probably know the company as the name behind Tylenol, Band-Aid, and talcum powder. Johnson & Johnson actually spun off these consumer-facing brands into a stand-alone business called Kenvue back in 2023, leaving behind a prescription drug and medical device operation that some investors never knew existed. As was noted, most investors might struggle to name even just one of its drugs.
Nevertheless, it's there, and it's growing. Last quarter's operational revenue growth of 5.7% extends Q1's and last year's pace, led by the company's oncology arm, and particularly its cancer-fighting Darzalex, which saw global sales growth of nearly 19% in Q2.
Today's Change
(
1.56
%) $
4.04
Current Price
$
263.31
And that's important. Although its oncology business has been an important profit center for some time, Johnson & Johnson aims to sell at least $50 billion in cancer drugs per year by 2030, making it the biggest name in the business.
For perspective on that figure and its growth, the company is on pace to drive record-breaking revenue of just over $100 billion this year, with roughly $30 billion of that being cancer-related.
The thing is, with its oncology business now persistently growing at a rate in the high teens, Johnson & Johnson can reach this goal, more than offsetting the rapid deterioration of Stelara's sales now that the anti-inflammation drug's patents have expired.
Still a dividend holding, but one being rebuilt to extend an impressive track record This performance still won't qualify J&J as the sort of growth name that most investors envision when looking for a new growth investment. It's still predominantly a dividend-paying value stock, although a very good one. Indeed, with a track record of 64 consecutive years' worth of per-share dividend increases (adjusted for the Kenvue spinoff), it easily qualifies as a Dividend King.
This oncology-driven revenue growth, however, sets the stage for continued dividend increases.
And the underlying opportunity is certainly solid. An outlook from Precedence Research suggests the worldwide cancer treatment market is poised to grow at an average annualized rate of 11.3% through 2035, from $280 billion this year to over $730 billion per year at the end of this time frame. Johnson & Johnson just needs to make sure it continues capturing its fair share of this growth.
Key Takeaways Johnson & Johnson's Innovative Medicine sales rose 6.8% operationally to $16.38 billion in Q2 2026.JNJ's growth was led by Darzalex, Tremfya, Erleada and newer drugs despite Stelara's sharp decline.Johnson & Johnson expects key drugs and new launches to support above-market growth through 2026. Johnson & Johnson (JNJ - Free Report) , via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key areas, including neuroscience, cardiovascular and metabolic diseases, immunology, oncology, pulmonary hypertension and infectious diseases.
J&J’s Innovative Medicines/Pharma segment is the company’s primary growth engine, clearly outperforming its MedTech segment, despite the impact of biosimilar and generic competition on sales of some key drugs like Stelara, Remicade and Zytiga.
J&J’s Innovative Medicine Segment’s Q2 PerformanceJ&J’s Innovative Medicine segment delivered another quarter of healthy operational growth in the second quarter as sales rose 6.8% on an operational basis (excluding the impact of currency) to $16.38 billion.
On an organic basis, sales rose 6.9% despite the loss of exclusivity (“LOE”) of the multi-billion-dollar product, Stelara.
Higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment’s growth. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. These gains were partly offset by lower sales of Stelara, Remicade, Imbruvica and Zytiga.
Sales of blockbuster multiple myeloma treatment, Darzalex, rose 18.9% to $4.21 billion in the quarter. Tremfya remained another key growth driver, with sales rising 72.5% to $2.05 billion. Erleada sales increased 9.5% to $995 million.
Stelara’s sales fell 55.2% to $740 million. Stelara’s LOE negatively impacted the Innovative Medicines segment’s growth by 760 basis points and total revenues by 460 basis points in the second quarter.
J&J’s Innovative Medicine Segment’s Outlook for H2J&J expects its Innovative Medicine segment to remain a key growth driver in the second half of 2026. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato, Carvykti and Erleada, as well as increased contribution from new launches like Icotyde, Rybrevant and Inlexzo, which can offset the ongoing impact of Stelara biosimilar competition. On the second-quarter conference call, J&J said that it is seeing strong launches of all these new drugs, Inlexzo, Icotyde and Imaavy.
However, other than the Stelara LOE impact, J&J expects generic impact for both Simponi and Opsumit to begin in 2026 as the drugs lose patent protection.
Overall, J&J expects continued above-market growth for the Innovative Medicine segment through the remainder of 2026. In fact, Innovative Medicine is expected to remain J&J's primary growth engine for the foreseeable future.
J&J Key CompetitorsImmunology and oncology are J&J’s key areas. Other large drugmakers with a strong presence in the oncology market include Novartis, AstraZeneca (AZN - Free Report) , AbbVie (ABBV - Free Report) , Amgen (AMGN - Free Report) , Merck, Bristol-Myers, Roche and Pfizer. In immunology, AbbVie, Amgen, Sanofi, AstraZeneca and Pfizer hold a strong position.
JNJ’s Price Performance, Valuation and EstimatesJ&J’s shares have outperformed the industry so far this year. The stock has risen 26.7% this year compared with 11.8% appreciation of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 21.07 forward earnings, higher than 18.72 for the industry. The stock is also trading above its five-year mean of 15.65.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $11.58 per share to $11.65 per share over the past 30 days, while that for 2027 earnings has gone up from $12.65 per share to $12.80 over the same time frame.
Image Source: Zacks Investment Research
J&J has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights, opens new tab
CompaniesJuly 24 (Reuters) - The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue's (KVUE.N), opens new tab Tylenol with the nonsteroidal anti-inflammatory drug naproxen for up to 12 hours of pain relief.
Here are some details:
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The pill can be used by adults and children aged 12 and older for headaches, back pain, muscle aches, toothaches, menstrual cramps and minor arthritis pain.
The FDA said the approval aligns with Trump's "The Great Healthcare Plan," a federal effort to make more verified safe pharmaceutical drugs available for over-the-counter purchase.
Each pill contains 325 milligrams of Tylenol and 110 milligrams of naproxen sodium.
Tylenol has been under scrutiny after U.S. health officials raised concerns about an alleged link between Tylenol use during pregnancy and autism. There is no firm scientific evidence of such a link.
The debate has also triggered legal action, as Texas sued Kenvue over alleged failures to warn pregnant consumers, and a U.S. appeals court this month revived more than 500 private lawsuits making similar claims.
Kenvue agreed last November to be acquired by Kleenex tissue maker Kimberly-Clark (KMB.O), opens new tab for more than $40 billion. The transaction is expected to close this year.
Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Bank of Nova Scotia reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 36.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 761,803 shares of the company’s stock after selling 433,751 shares during the quarter. Bank of Nova Scotia’s holdings in Johnson & Johnson were worth $186,215,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in JNJ. Brighton Jones LLC increased its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the period. United Bank boosted its position in Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares during the period. Sivia Capital Partners LLC grew its stake in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares in the last quarter. Wealth Group Ltd. increased its position in shares of Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after acquiring an additional 168 shares during the period. Finally, Schnieders Capital Management LLC. raised its stake in shares of Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after acquiring an additional 6,584 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson News Roundup Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: The FDA granted marketing authorization for J&J’s OTTAVA robotic surgical system, a potentially meaningful new business in soft-tissue robotics that could expand the MedTech division. Reuters article Positive Sentiment: J&J also reported encouraging late-stage data for its multiple myeloma therapies Tecvayli and Talvey, with the MonumenTAL-6 study showing large reductions in progression risk and death, strengthening the company’s oncology pipeline. PR Newswire article Positive Sentiment: Investors are also responding to J&J’s recent quarterly earnings beat and upbeat 2026 outlook, which has boosted sentiment around the stock and drawn interest from ETF investors. Yahoo Finance article Positive Sentiment: J&J raised its dividend, reinforcing its appeal as a defensive income stock and supporting demand from dividend-focused investors. Yahoo Finance article Neutral Sentiment: Several articles were commentary pieces discussing J&J’s valuation, ETF exposure, and investor attention, but they do not add a new fundamental catalyst on their own. MarketBeat article Negative Sentiment: A Reuters report said a judge cast doubt on roughly 69,000 talc-related cancer claims, which could still keep legal uncertainty in focus despite being framed as a procedural win for J&J. Reuters article Analysts Set New Price Targets Several research analysts recently commented on the company. Royal Bank Of Canada boosted their target price on Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Bank of America upped their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research note on Friday, July 10th. Argus raised their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Scotiabank reiterated an “outperform” rating and issued a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Guggenheim reissued a “buy” rating and issued a $270.00 price objective on shares of Johnson & Johnson in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $265.30.
Get Our Latest Stock Analysis on JNJ
Insider Activity In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.
Johnson & Johnson Trading Up 1.5% JNJ opened at $259.34 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $164.23 and a one year high of $269.43. The company has a market cap of $624.29 billion, a P/E ratio of 30.05, a PEG ratio of 2.43 and a beta of 0.24. The business’s 50-day simple moving average is $241.98 and its 200-day simple moving average is $236.13.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The firm’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.68 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.
Johnson & Johnson Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Read More Five stocks we like better than Johnson & Johnson Premium Retail’s Stress Test Is Separating Winners From Losers D-Wave Quantum or a Quantum ETF: Which Is the Better Bet? GE Vernova Just Sent a Mixed AI Signal to Investors Alphabet Crushed Earnings, But One Number Spooked the Market Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of Nova Scotia Lowers Stock Position in Costco Wholesale Corporation $COST
NEXT HEADLINE »Bank of Nova Scotia Reduces Position in Merck & Co., Inc. $MRK
Key Takeaways JNJ beat Q2 earnings and sales estimates, driven by strength in Tremfya, Darzalex and other key drugs.JNJ raised its 2026 outlook as it advances new launches, FDA filings and eyes the Firefly Bio acquisition. ETFs like IHE offer exposure to Johnson & Johnson for investors seeking diversified healthcare access. Medtech giant Johnson & Johnson (JNJ - Free Report) reported better-than-expected second-quarter 2026 results, surpassing Wall Street estimates on both the top and bottom lines. The quarterly performance was primarily driven by strong growth in the immunology drug Tremfya and cancer blockbuster Darzalex.
Despite reporting such an impressive quarterly performance, this drugmaker slipped 1.5% at the bourses following the earnings announcement. This dip, largely attributed to a notable sales miss in its MedTech division and a 2% slump in its Cardiovascular sales, was short-lived, as the stock regained its balance the following day, gaining 1.2%.
Notably, JNJ has gained 3.5% since reporting its second-quarter results a week ago. The stock is now up more than 20% year to date, comfortably outperforming the S&P 500's 9.3% return.
Against this backdrop, for investors looking to capitalize on JNJ's raised earnings outlook for the year, backed by its dominant position in the Pharma and MedTech industries, healthcare exchange-traded funds (ETFs) offer a lower-risk entry point to gain exposure to this healthcare giant before the next major rally, particularly for those seeking to avoid single-stock idiosyncratic risk.
But before suggesting a few such healthcare ETFs that deserve a place in your portfolio, let us take a look at JNJ's overall second-quarter performance.
A Brief Look at JNJ's Q2 ResultsJNJ's second-quarter earnings per share (EPS) of $2.90 beat the Zacks Consensus Estimate by 2.1%, while sales outpaced the consensus mark by 0.5%.
The combination of TALVEY and DARZALEX delivered deep and durable responses with more than 80% of patients progression-free at 2 years and overall survival up to 89%, as per the second-quarter data.
In solid tumors, JNJ continued to see strong performance from ERLEADA and RYBREVANT. In bladder cancer, nearly one in three eligible patients started on an INLEXZO regimen and new patient insertions grew approximately 75% in the second quarter versus the prior quarter.
In Immunology, JNJ’s TREMFYA remained the fastest-growing advanced therapy in both Crohn's disease and ulcerative colitis, delivering exceptional overall sales growth of 71%. In Neuroscience, both SPRAVATO and CAPLYTA delivered strong performance in the second quarter, with CAPLYTA's new patient starts surging 122% year over year.
In Cardiovascular, VARIPULSE, JNJ’s pulsed-field ablation platform for atrial fibrillation, showed strong momentum with more than 85,000 patients now treated worldwide.
JNJ debuted its CARTOSOUND SONATA, bringing new AI-powered imaging and mapping capabilities to electrophysiology. The company also received FDA authorization for its dual-energy THERMOCOOL SMARTTOUCH SF platform, which integrates pulsed-field and radiofrequency energy in a single system to give physicians greater flexibility in tailoring ablation treatments for patients.
In Circulatory Restoration, JNJ’s global launch of Shockwave C2 Aero expanded the healthcare giant’s ability to treat more complex coronary disease and broadened the reach of its intravascular lithotripsy platform.
J&J's management expects to receive FDA regulatory approval for IMAAVY as the first-ever treatment for patients with warm autoimmune hemolytic anemia, a rare and serious autoantibody disease, in the second half of 2026.
The company also projects FDA approval for its OTTAVA robotic surgical system and the EMEA launch of ETHICON 4000 this year.
JNJ’s planned acquisition of Firefly Bio, expected to be closed in the third quarter of 2026, should add a proprietary platform designed to target KRAS-driven solid tumors, which are typically more difficult to treat, thereby further diversifying the company’s oncology pipeline.
Market Reaction Post Q2 EarningsFollowing J&J's upbeat Q2 results, Bernstein raised its price target for the pharma giant to $261 from $251 while maintaining a Market Perform rating, citing solid underlying medical technology trends to drive the stock's performance (as cited in Investing.com).
JNJ-Heavy ETFs to BuyiShares U.S. Pharmaceuticals ETF (IHE - Free Report)
This fund, with net assets worth $1.44 billion, provides exposure to 56 U.S. domestic drug manufacturers and vaccine producers. Of these, Johnson and Johnson takes the first spot, accounting for a 21.72% share.
IHE has rallied 18.7% year to date and charges 38 basis points (bps) in fees. IHE holds a Zacks Rank #2 (Buy) and traded at a volume of 0.13 million shares in the last trading session.
State Street Health Care Select Sector SPDR ETF (XLV - Free Report)
This fund, with assets under management (AUM) of $41.69 billion, provides exposure to 60 companies across pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, life sciences tools and services, and health care technology industries. Of these, Johnson and Johnson takes the second spot, accounting for a 10.42% share.
XLV has risen 3% year to date and charges 8 bps in fees. It traded in a heavy volume of around 5.60 million shares in the last trading session. XLV sports a Zacks Rank #1 (Strong Buy).
Vanguard Health Care ETF (VHT - Free Report)
This fund, with net assets worth $20.4 billion, provides exposure to 423 companies that manufacture health care equipment and supplies or that provide health care-related services, and companies that are primarily involved in the research, development, production, and marketing of pharmaceuticals and biotechnology products. Of these, Johnson and Johnson takes the second spot, accounting for an 8.87% share.
VHT has risen 4.2% year to date and charges 9 bps in fees. It traded in a volume of around 0.28 million shares in the last trading session. VHT sports a Zacks Rank #1.
Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the company's leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journey RARITAN, N.J., July 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and TALVEY® + pomalidomide in adult patients with relapsed or refractory multiple myeloma (RRMM) who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide.1 The study demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival for both investigational arms compared with investigator's choice standard of care.
ABN Amro Investment Solutions increased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 164,373 shares of the company’s stock after acquiring an additional 9,521 shares during the quarter. ABN Amro Investment Solutions’ holdings in Johnson & Johnson were worth $40,179,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blueline Advisors LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $25,000. Cresta Advisors Ltd. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. DecisionPoint Financial LLC grew its stake in shares of Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after acquiring an additional 75 shares during the last quarter. Family CFO Inc acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $31,000. Finally, Bay Harbor Wealth Management LLC increased its position in Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after acquiring an additional 49 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insider Activity at Johnson & Johnson In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth Several analysts have issued reports on JNJ shares. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Royal Bank Of Canada upped their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Bank of America increased their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research note on Friday, July 10th. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. Finally, Wells Fargo & Company boosted their price target on Johnson & Johnson from $263.00 to $272.00 and gave the company an “overweight” rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $265.30.
Read Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Price Performance Shares of JNJ stock opened at $255.71 on Thursday. The stock’s fifty day simple moving average is $241.40 and its 200 day simple moving average is $235.76. Johnson & Johnson has a one year low of $164.23 and a one year high of $269.43. The firm has a market cap of $615.56 billion, a price-to-earnings ratio of 29.63, a P/E/G ratio of 2.38 and a beta of 0.24. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same period in the prior year, the company posted $2.77 earnings per share. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts expect that Johnson & Johnson will post 11.68 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is 62.11%.
Johnson & Johnson News Summary Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: The FDA approved J&J’s OTTAVA robotic surgery system, opening the door for Johnson & Johnson to compete in robotic soft-tissue surgery and potentially expand its medtech growth runway. Reuters article on OTTAVA approval Positive Sentiment: Investors are also encouraged by the prospect of a phased launch of OTTAVA with select customers, suggesting J&J is preparing a commercial rollout after securing clearance. Medical Device Network article on OTTAVA launch plans Positive Sentiment: J&J also continues to look like a defensive income stock, with a newly declared quarterly dividend reinforcing its appeal to dividend-focused investors. Yahoo Finance dividend article Neutral Sentiment: A federal judge cast doubt on roughly 69,000 talc-related cancer claims, but the court did not dismiss the litigation outright, so the legal overhang remains a mixed but potentially improving risk for J&J. Reuters talc litigation article Johnson & Johnson Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Recommended Stories Five stocks we like better than Johnson & Johnson Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINESchneider National (SNDR) Expected to Announce Quarterly Earnings on Thursday
NEXT HEADLINE »ABN Amro Investment Solutions Purchases 6,126 Shares of CBRE Group, Inc. $CBRE
Arvest Bank Trust Division decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 20.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 60,784 shares of the company’s stock after selling 15,867 shares during the quarter. Johnson & Johnson makes up 0.8% of Arvest Bank Trust Division’s investment portfolio, making the stock its 29th largest position. Arvest Bank Trust Division’s holdings in Johnson & Johnson were worth $14,858,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Greenberg Financial Group bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $954,000. World Investment Advisors increased its holdings in Johnson & Johnson by 19.6% during the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after acquiring an additional 26,450 shares during the period. Benchmark Financial LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at $554,000. Robinhood Asset Management LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $11,853,000. Finally, Principal Financial Group Inc. boosted its position in shares of Johnson & Johnson by 0.8% during the 4th quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock valued at $705,736,000 after acquiring an additional 28,370 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.
Insider Activity In related news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.
Analysts Set New Price Targets JNJ has been the topic of a number of recent analyst reports. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Guggenheim restated a “buy” rating and set a $270.00 price target on shares of Johnson & Johnson in a research report on Friday, July 17th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. HSBC set a $290.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Monday, July 6th. Finally, Barclays upped their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $265.30.
Check Out Our Latest Stock Report on Johnson & Johnson
Key Headlines Impacting Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: The FDA approved J&J’s OTTAVA robotic surgery system, opening the door for Johnson & Johnson to compete in robotic soft-tissue surgery and potentially expand its medtech growth runway. Reuters article on OTTAVA approval Positive Sentiment: Investors are also encouraged by the prospect of a phased launch of OTTAVA with select customers, suggesting J&J is preparing a commercial rollout after securing clearance. Medical Device Network article on OTTAVA launch plans Positive Sentiment: J&J also continues to look like a defensive income stock, with a newly declared quarterly dividend reinforcing its appeal to dividend-focused investors. Yahoo Finance dividend article Neutral Sentiment: A federal judge cast doubt on roughly 69,000 talc-related cancer claims, but the court did not dismiss the litigation outright, so the legal overhang remains a mixed but potentially improving risk for J&J. Reuters talc litigation article Johnson & Johnson Price Performance JNJ stock opened at $255.71 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1 year low of $164.23 and a 1 year high of $269.43. The firm has a 50-day moving average of $241.40 and a 200 day moving average of $235.76. The company has a market cap of $615.56 billion, a P/E ratio of 29.63, a PEG ratio of 2.38 and a beta of 0.24.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 11.68 EPS for the current year.
Johnson & Johnson Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 62.11%.
Johnson & Johnson Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Further Reading Five stocks we like better than Johnson & Johnson Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEABN Amro Investment Solutions Takes Position in Globant S.A. $GLOB
NEXT HEADLINE »Assetmark Inc. Lowers Stock Holdings in Axon Enterprise, Inc $AXON
AR Asset Management Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 32,917 shares of the company’s stock after acquiring an additional 2,320 shares during the quarter. Johnson & Johnson comprises 1.6% of AR Asset Management Inc.’s investment portfolio, making the stock its 19th biggest holding. AR Asset Management Inc.’s holdings in Johnson & Johnson were worth $8,046,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. State Street Corp grew its position in shares of Johnson & Johnson by 1.3% in the 4th quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after buying an additional 1,663,782 shares during the last quarter. Auto Owners Insurance Co raised its stake in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Geode Capital Management LLC lifted its position in Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock valued at $11,967,947,000 after acquiring an additional 1,738,292 shares during the last quarter. Finally, Norges Bank acquired a new position in Johnson & Johnson in the fourth quarter valued at $6,924,523,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Stock Up 2.0% JNJ stock opened at $255.71 on Thursday. Johnson & Johnson has a one year low of $164.23 and a one year high of $269.43. The stock has a market capitalization of $615.56 billion, a PE ratio of 29.63, a price-to-earnings-growth ratio of 2.38 and a beta of 0.24. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a fifty day moving average of $241.40 and a 200-day moving average of $235.76.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The business’s revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts expect that Johnson & Johnson will post 11.68 EPS for the current year.
Johnson & Johnson Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.
Insiders Place Their Bets In related news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades A number of analysts have recently commented on JNJ shares. Johnson Rice upgraded Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 target price on the stock in a research report on Thursday, July 16th. Raymond James Financial raised their price target on Johnson & Johnson from $258.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research report on Wednesday, July 15th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Finally, TD Cowen lifted their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $265.30.
Read Our Latest Stock Analysis on JNJ
Trending Headlines about Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: The FDA approved J&J’s OTTAVA robotic surgery system, opening the door for Johnson & Johnson to compete in robotic soft-tissue surgery and potentially expand its medtech growth runway. Reuters article on OTTAVA approval Positive Sentiment: Investors are also encouraged by the prospect of a phased launch of OTTAVA with select customers, suggesting J&J is preparing a commercial rollout after securing clearance. Medical Device Network article on OTTAVA launch plans Positive Sentiment: J&J also continues to look like a defensive income stock, with a newly declared quarterly dividend reinforcing its appeal to dividend-focused investors. Yahoo Finance dividend article Neutral Sentiment: A federal judge cast doubt on roughly 69,000 talc-related cancer claims, but the court did not dismiss the litigation outright, so the legal overhang remains a mixed but potentially improving risk for J&J. Reuters talc litigation article Johnson & Johnson Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Articles Five stocks we like better than Johnson & Johnson Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
Aureus Asset Management LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 48.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,841 shares of the company’s stock after selling 9,325 shares during the period. Aureus Asset Management LLC’s holdings in Johnson & Johnson were worth $2,405,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the period. State Street Corp grew its holdings in shares of Johnson & Johnson by 1.3% in the fourth quarter. State Street Corp now owns 133,869,843 shares of the company’s stock worth $27,704,364,000 after acquiring an additional 1,663,782 shares during the period. Auto Owners Insurance Co grew its holdings in shares of Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the period. Geode Capital Management LLC increased its position in Johnson & Johnson by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock valued at $11,967,947,000 after acquiring an additional 1,738,292 shares during the last quarter. Finally, Norges Bank bought a new position in Johnson & Johnson in the fourth quarter valued at about $6,924,523,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Insider Buying and Selling In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.
Key Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: The FDA approved J&J’s OTTAVA robotic surgery system, opening the door for Johnson & Johnson to compete in robotic soft-tissue surgery and potentially expand its medtech growth runway. Reuters article on OTTAVA approval Positive Sentiment: Investors are also encouraged by the prospect of a phased launch of OTTAVA with select customers, suggesting J&J is preparing a commercial rollout after securing clearance. Medical Device Network article on OTTAVA launch plans Positive Sentiment: J&J also continues to look like a defensive income stock, with a newly declared quarterly dividend reinforcing its appeal to dividend-focused investors. Yahoo Finance dividend article Neutral Sentiment: A federal judge cast doubt on roughly 69,000 talc-related cancer claims, but the court did not dismiss the litigation outright, so the legal overhang remains a mixed but potentially improving risk for J&J. Reuters talc litigation article Johnson & Johnson Trading Up 2.0% Shares of Johnson & Johnson stock opened at $255.71 on Thursday. Johnson & Johnson has a fifty-two week low of $164.23 and a fifty-two week high of $269.43. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market capitalization of $615.56 billion, a P/E ratio of 29.63, a P/E/G ratio of 2.38 and a beta of 0.24. The company has a fifty day moving average of $241.40 and a 200 day moving average of $235.76.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same period last year, the firm earned $2.77 earnings per share. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 11.68 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.
Analyst Ratings Changes A number of research firms have issued reports on JNJ. HSBC set a $290.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Monday, July 6th. Guggenheim reiterated a “buy” rating and issued a $270.00 price objective on shares of Johnson & Johnson in a research note on Friday, July 17th. Citigroup raised their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. Finally, Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $265.30.
Get Our Latest Stock Analysis on Johnson & Johnson
About Johnson & Johnson (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also Five stocks we like better than Johnson & Johnson Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
A bottle of Johnson and Johnson Baby Powder is seen in a photo illustration taken in New York, February 24, 2016. REUTERS/Mike Segar/Illustration/File Photo Purchase Licensing Rights, opens new tab
CompaniesJuly 22 (Reuters) - A federal judge cast doubt on Wednesday on claims by approximately 69,000 people alleging that Johnson & Johnson's (JNJ.N), opens new tab baby powder and other talc products caused ovarian cancer, saying plaintiffs must provide more specific evidence or risk having their lawsuits dismissed.
U.S. Magistrate Judge Rukhsanah Singh in Trenton, New Jersey, said that recent testimony by two of the plaintiffs' experts raised doubts about whether any plaintiffs can provide evidence admissible in court "that talcum powder use specifically caused her ovarian cancer."
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The two experts, Judith Wolf and Daniel Clarke-Pearson, testified in May in preparation for a set of six "bellwether," or test, trials for the thousands of court cases that have been consolidated in New Jersey's federal court. Verdicts in bellwether trials are used to assess the potential value of remaining claims and guide settlement talks.
J&J has denied the allegations that its talc products caused cancer, saying that talc was safe and did not contain asbestos.
A spokesperson for the company did not immediately respond to a request for comment, nor did a lead attorney for the plaintiffs.
Wolf and Clarke-Pearson said they could not completely rule out other possible causes of the plaintiffs' ovarian cancer, according to Singh's opinion.
"If such uncertainty is indeed reality, then how can any plaintiff here meet her burden on the merits of her claim?" Singh wrote.
Singh said that the debate over causation would not lead to "instant dismissal" of the thousands of cases in the consolidated federal litigation. The judge ordered plaintiffs to respond by November 19, and to explain why their case should not be dismissed over the failure to provide an admissible expert opinion that J&J talc caused their specific cancer.
Reporting by Dietrich Knauth in New York; Editing by Alexia Garamfalvi and Will Dunham
Our Standards: The Thomson Reuters Trust Principles., opens new tab
The marketing clearance encompasses multiple general surgery procedures.
The medical technology giant will initiate a commercial rollout with select U.S. facilities, prioritizing initial customer success while working to expand regulatory approvals and procedural indications globally.
An additional U.S. clinical study evaluating the platform for inguinal hernia procedures is currently underway.
Architecture And Space-Saving DesignBuilt to support modern operating room workflows, OTTAVA incorporates four robotic arms directly into the operating table.
The setup reduces the system’s physical footprint by 30% to 50% compared to conventional boom- or cart-mounted robotic systems, giving surgical personnel more space to move, communicate, and deliver care.
Advanced software controls coordinate the table-integrated arms to allow automated procedural setups.
A synchronized feature known as twin motion coordinates table and arm movements simultaneously, enabling patient repositioning and multi-quadrant surgical access without extensive manual adjustments.
Surgical Instruments And Digital EcosystemThe platform includes updated surgical instrumentation, featuring monopolar curved scissors designed for complete cuts and a specialized two-in-one needle driver engineered to minimize accidental suture damage.
To support clinical teams, the system links to the secure Polyphonic digital ecosystem, which consolidates learning materials, media, and data-driven insights.
Additionally, a comprehensive training framework combining virtual, immersive, and hands-on instruction will assist clinicians in adopting the technology safely and effectively.
JNJ Stock Price Activity: Johnson & Johnson shares were up 2.00% at $255.61 at the time of publication on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
Johnson & Johnson (JNJ - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this world's biggest maker of health care products have returned +4.8%, compared to the Zacks S&P 500 composite's +0.3% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Johnson & Johnson falls in, has gained 9.1%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Johnson & Johnson is expected to post earnings of $3.04 per share, indicating a change of +8.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +1% over the last 30 days.
The consensus earnings estimate of $11.65 for the current fiscal year indicates a year-over-year change of +8%. This estimate has changed +0.9% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $12.8 indicates a change of +9.9% from what Johnson & Johnson is expected to report a year ago. Over the past month, the estimate has changed +1.2%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Johnson & Johnson.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Johnson & Johnson, the consensus sales estimate of $25.36 billion for the current quarter points to a year-over-year change of +5.7%. The $101.01 billion and $107.24 billion estimates for the current and next fiscal years indicate changes of +7.2% and +6.2%, respectively.
Last Reported Results and Surprise HistoryJohnson & Johnson reported revenues of $25.31 billion in the last reported quarter, representing a year-over-year change of +6.6%. EPS of $2.9 for the same period compares with $2.77 a year ago.
Compared to the Zacks Consensus Estimate of $25.18 billion, the reported revenues represent a surprise of +0.53%. The EPS surprise was +2.11%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Johnson & Johnson is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Johnson & Johnson. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the world's first table-integrated soft tissue robotic system. The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesio.
People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov Purchase Licensing Rights, opens new tab
CompaniesJuly 22 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, clearing the way for the healthcare conglomerate to enter the soft-tissue robotic surgery market.
The Ottava robotic surgical system was authorized for use in multiple general surgery procedures in the upper abdomen, including gastric bypass, gastrectomy, gallbladder removal, gastric sleeve surgery, appendectomy and hiatal hernia repair.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
J&J said it would begin a U.S. commercial launch with select customers, while working to expand the system into additional indications and regulatory markets.
Reporting by Puyaan Singh in Bengaluru; Editing by Joyjeet Das
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Johnson & Johnson JNJ announced robust second-quarter 2026 results on July 15, beating estimates for both earnings and sales. While earnings rose 4.7%, sales rose 6.6% from the year-ago period.
California Public Employees Retirement System lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 19.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,994,988 shares of the company’s stock after selling 1,444,253 shares during the period. Johnson & Johnson makes up 0.9% of California Public Employees Retirement System’s portfolio, making the stock its 15th biggest position. California Public Employees Retirement System owned approximately 0.25% of Johnson & Johnson worth $1,465,415,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also modified their holdings of the business. Quadrant Private Wealth Management LLC boosted its position in shares of Johnson & Johnson by 0.5% during the first quarter. Quadrant Private Wealth Management LLC now owns 22,377 shares of the company’s stock worth $5,470,000 after buying an additional 109 shares during the period. Ranch Capital Advisors Inc. grew its position in shares of Johnson & Johnson by 3.7% in the 1st quarter. Ranch Capital Advisors Inc. now owns 15,940 shares of the company’s stock valued at $3,896,000 after acquiring an additional 570 shares during the period. Heartland Bank & Trust Co raised its stake in Johnson & Johnson by 70.9% in the first quarter. Heartland Bank & Trust Co now owns 15,382 shares of the company’s stock valued at $3,760,000 after buying an additional 6,381 shares during the period. Zhang Financial LLC lifted its stake in shares of Johnson & Johnson by 35.3% during the 1st quarter. Zhang Financial LLC now owns 18,324 shares of the company’s stock worth $4,479,000 after buying an additional 4,783 shares during the last quarter. Finally, Simon Quick Advisors LLC grew its position in shares of Johnson & Johnson by 1.6% in the first quarter. Simon Quick Advisors LLC now owns 14,067 shares of the company’s stock valued at $3,439,000 after purchasing an additional 219 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Johnson & Johnson In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.
Johnson & Johnson Stock Performance NYSE JNJ opened at $252.93 on Monday. The firm’s fifty day moving average price is $239.82 and its two-hundred day moving average price is $234.82. The stock has a market cap of $608.86 billion, a PE ratio of 29.31, a PEG ratio of 2.39 and a beta of 0.24. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $162.78 and a fifty-two week high of $269.43.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same period in the prior year, the company earned $2.77 EPS. Johnson & Johnson’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.68 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s payout ratio is 62.11%.
Analyst Upgrades and Downgrades A number of equities research analysts have recently weighed in on the company. Daiwa Securities Group lifted their target price on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a report on Thursday, April 16th. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Scotiabank reaffirmed an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a report on Thursday. Citigroup increased their price target on Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $265.30.
Read Our Latest Research Report on JNJ
Key Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why About Johnson & Johnson (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Read More Five stocks we like better than Johnson & Johnson Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEMarkel Group Inc. $MKL Shares Sold by California Public Employees Retirement System
NEXT HEADLINE »California Public Employees Retirement System Purchases 6,563 Shares of IQVIA Holdings Inc. $IQV
Clifford Swan Investment Counsel LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 211,196 shares of the company’s stock after selling 3,553 shares during the period. Johnson & Johnson comprises approximately 1.8% of Clifford Swan Investment Counsel LLC’s holdings, making the stock its 10th largest position. Clifford Swan Investment Counsel LLC’s holdings in Johnson & Johnson were worth $51,625,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Blueline Advisors LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at $25,000. Cresta Advisors Ltd. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $26,000. DecisionPoint Financial LLC increased its position in shares of Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the last quarter. Family CFO Inc purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $31,000. Finally, Bay Harbor Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the period. 69.55% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades Several analysts recently issued reports on the stock. Bank of America boosted their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research report on Friday, July 10th. Citigroup raised their target price on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. The Goldman Sachs Group restated a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research report on Thursday. Daiwa Securities Group increased their price objective on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. Finally, Weiss Ratings cut shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $265.30.
View Our Latest Analysis on JNJ
Insider Buying and Selling at Johnson & Johnson In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.
Johnson & Johnson Trading Down 0.0% Shares of JNJ stock opened at $252.93 on Monday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $608.86 billion, a price-to-earnings ratio of 29.31, a price-to-earnings-growth ratio of 2.39 and a beta of 0.24. Johnson & Johnson has a 12-month low of $162.78 and a 12-month high of $269.43. The stock’s 50-day moving average price is $239.82 and its 200-day moving average price is $234.82.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter last year, the business earned $2.77 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts predict that Johnson & Johnson will post 11.68 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 62.11%.
Key Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Johnson & Johnson Company Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Read More Five stocks we like better than Johnson & Johnson Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia Public Employees Retirement System Purchases 6,563 Shares of IQVIA Holdings Inc. $IQV
NEXT HEADLINE »California Public Employees Retirement System Purchases 149,508 Shares of Devon Energy Corporation $DVN
Dorsey Wright & Associates boosted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 48.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,443 shares of the company’s stock after purchasing an additional 8,953 shares during the period. Dorsey Wright & Associates’ holdings in Johnson & Johnson were worth $6,708,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. Auto Owners Insurance Co boosted its stake in shares of Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after buying an additional 69,108,368 shares during the last quarter. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at $6,924,523,000. Capital World Investors bought a new position in Johnson & Johnson in the fourth quarter valued at about $2,005,942,000. Diamant Asset Management Inc. boosted its position in Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after purchasing an additional 4,454,778 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after purchasing an additional 3,731,074 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson News Summary Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Wall Street Analyst Weigh In Several equities research analysts have recently commented on JNJ shares. Guggenheim reaffirmed a “buy” rating and set a $270.00 price target on shares of Johnson & Johnson in a research report on Friday. The Goldman Sachs Group restated a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday. Barclays upped their target price on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Sanford C. Bernstein increased their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 15th. Finally, Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $265.30.
Check Out Our Latest Analysis on Johnson & Johnson
Insider Buying and Selling In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.
Johnson & Johnson Price Performance Shares of NYSE:JNJ opened at $252.93 on Monday. The company has a market capitalization of $608.86 billion, a P/E ratio of 29.31, a P/E/G ratio of 2.39 and a beta of 0.24. Johnson & Johnson has a 1-year low of $162.78 and a 1-year high of $269.43. The firm’s 50 day simple moving average is $239.82 and its two-hundred day simple moving average is $234.82. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts expect that Johnson & Johnson will post 11.68 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.
Johnson & Johnson Company Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Further Reading Five stocks we like better than Johnson & Johnson Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Sells 62,637 Shares of NXP Semiconductors N.V. $NXPI
NEXT HEADLINE »California Public Employees Retirement System Sells 137,675 Shares of Cloudflare, Inc. $NET
Bartlett & CO. Wealth Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 231,580 shares of the company’s stock after selling 11,088 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Johnson & Johnson were worth $51,920,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in JNJ. Blueline Advisors LLC bought a new position in Johnson & Johnson during the 4th quarter worth about $25,000. Cresta Advisors Ltd. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $26,000. DecisionPoint Financial LLC grew its holdings in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after buying an additional 75 shares in the last quarter. Family CFO Inc acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $31,000. Finally, Bay Harbor Wealth Management LLC lifted its stake in Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares in the last quarter. 69.55% of the stock is owned by institutional investors.
Insider Buying and Selling In other news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.
Johnson & Johnson Stock Down 0.0% NYSE:JNJ opened at $252.93 on Monday. The firm has a market capitalization of $608.86 billion, a price-to-earnings ratio of 29.31, a price-to-earnings-growth ratio of 2.39 and a beta of 0.24. Johnson & Johnson has a twelve month low of $162.78 and a twelve month high of $269.43. The stock’s 50 day moving average price is $239.82 and its two-hundred day moving average price is $234.82. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the prior year, the business posted $2.77 EPS. The business’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts expect that Johnson & Johnson will post 11.68 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.
Wall Street Analyst Weigh In JNJ has been the subject of several research reports. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $263.00 to $272.00 and gave the stock an “overweight” rating in a research report on Thursday. Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $265.30.
Get Our Latest Stock Report on JNJ
Key Headlines Impacting Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Johnson & Johnson Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Recommended Stories Five stocks we like better than Johnson & Johnson Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAstrazeneca Plc $AZN Shares Acquired by DekaBank Deutsche Girozentrale
Johnson & Johnson (JNJ +1.23%) has been a top-performing stock this year. Investors, in many cases rotating out of riskier assets, have looked for companies with a strong track record of earnings growth, solid competitive positions, and a revenue stream they can count on -- and J&J fits the bill.
As a healthcare player, J&J sells pharmaceuticals and medical devices that ensure a certain level of revenue, as patients need their procedures no matter what direction the stock market takes. Over time, the company's in-house research and acquisitions have built a market-leading portfolio that has kept earnings climbing. Investors, concerned about geopolitical uncertainties and risks to the artificial intelligence (AI) growth story, turned to J&J in the first half, sending the stock to a 22% gain.
Last week, J&J delivered a blowout earnings report and increased full-year forecasts. But is it too late to buy this healthcare giant? Let's find out.
Image source: Getty Images.
A household name You might know J&J best for consumer products that you regularly use, from Band-Aid brand bandages to Tylenol. They've made J&J a household name. But the company actually spun off its consumer health business, which includes these products, as Kenvue a few years ago. This was in an effort to boost growth, with the idea of dedicating all of its resources to the higher-growth areas of pharmaceuticals and medtech.
The Kenvue spinoff came at a key moment, as J&J prepared to lose exclusivity of its blockbuster immunology drug Stelara. At its peak in 2024, Stelara brought in more than $10 billion. But the impending entry of rivals meant that Stelara sales would drop drastically.
J&J's move was a wise one, and the latest quarter illustrates this. Solid performance from immunology drug Tremfya and leading multiple myeloma drug Darzalex compensated for Stelara declines and drove more than 6% growth to $25 billion in total revenue -- keeping J&J on track to reach its goal of $100 billion in annual revenue. Darzalex revenue jumped 18% to more than $4.2 billion in the quarter, while Tremfya soared 72% to $2 billion.
Today's Change
(
1.23
%) $
3.07
Current Price
$
253.04
A recent headwind J&J faced one headwind in particular in the quarter. The medtech division saw some weakness -- in an interview with CNBC, chief financial officer Joseph Wolk said sales of Abiomed heart pumps slipped after the release of a study questioning the use of Impella pumps during some high-risk procedures. Wolk said J&J plans to release data in the first half of next year that should alleviate concerns. It's important to remember that the company has 28 products or platforms that bring in revenue of at least $1 billion, offering it the fuel needed for ongoing growth.
J&J increased its full-year sales guidance to $101.1 billion at the midpoint from the previous estimate of $100.8. And it boosted adjusted earnings per share guidance to $11.68 at the midpoint from $11.55.
Should you buy J&J? Now, let's return to our question: Is it too late to buy shares of this healthcare giant after its strong run so far this year?
Today, J&J isn't dirt cheap. In fact, it's trading close to its highest in relation to forward earnings estimates.
JNJ PE Ratio (Forward) data by YCharts
It's possible that, given this valuation level, the stock may dip in the weeks or months to come, offering investors a better buying opportunity. Value investors, for example, probably should wait before jumping to get in on J&J stock at this level.
That said, it's important to note that J&J offers investors many strengths, from its broad portfolio of blockbuster products to leadership in key treatment areas such as multiple myeloma and immunology, through the two top drugs mentioned above. J&J is also a Dividend King, having increased its dividend payments for more than 50 consecutive years. So, investors focused on dividend growth may find it worthwhile to buy shares of J&J even at today's valuation -- it's high, but not outrageous.
All of this means your investment style and priorities should guide your decision. The best news of all is that this top pharma stock likely has room to run over the long term.
Johnson & Johnson (NYSE:JNJ – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twenty-six brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $265.3043.
A number of research analysts have recently weighed in on the stock. Raymond James Financial raised their price objective on shares of Johnson & Johnson from $258.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday. Citigroup raised their price target on Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Finally, Bank of America increased their price objective on Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research note on Friday, July 10th.
Get Our Latest Stock Report on Johnson & Johnson
Key Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Insider Activity at Johnson & Johnson In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.
Institutional Trading of Johnson & Johnson Several hedge funds and other institutional investors have recently bought and sold shares of the company. Blueline Advisors LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $25,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson during the fourth quarter worth about $26,000. DecisionPoint Financial LLC boosted its stake in Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after buying an additional 75 shares during the last quarter. Family CFO Inc purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $31,000. Finally, Bay Harbor Wealth Management LLC increased its stake in shares of Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance Johnson & Johnson stock opened at $252.93 on Thursday. The firm has a market capitalization of $608.86 billion, a PE ratio of 29.31, a P/E/G ratio of 2.39 and a beta of 0.24. Johnson & Johnson has a 52 week low of $162.78 and a 52 week high of $269.43. The firm’s 50-day simple moving average is $239.82 and its 200 day simple moving average is $234.63. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The firm had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same period last year, the firm posted $2.77 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts predict that Johnson & Johnson will post 11.68 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.
Johnson & Johnson Company Profile (Get Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also Five stocks we like better than Johnson & Johnson Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
Gerald Baker Financial Group LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 17,679 shares of the company’s stock, valued at approximately $4,321,000. Johnson & Johnson makes up 1.5% of Gerald Baker Financial Group LLC’s holdings, making the stock its 22nd largest position.
Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC raised its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. United Bank boosted its stake in Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after buying an additional 692 shares in the last quarter. Wealth Group Ltd. grew its holdings in shares of Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after buying an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. raised its position in shares of Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after buying an additional 6,584 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insider Activity at Johnson & Johnson In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.
Johnson & Johnson Price Performance Shares of JNJ stock opened at $252.93 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The company has a market capitalization of $608.86 billion, a PE ratio of 29.31, a price-to-earnings-growth ratio of 2.39 and a beta of 0.24. The firm’s 50-day moving average is $239.82 and its two-hundred day moving average is $234.63. Johnson & Johnson has a 12 month low of $162.78 and a 12 month high of $269.43.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts predict that Johnson & Johnson will post 11.68 earnings per share for the current year.
Johnson & Johnson Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.
Johnson & Johnson News Roundup Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Wall Street Analyst Weigh In JNJ has been the topic of a number of recent research reports. Argus boosted their price target on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Citigroup raised their target price on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Bank of America boosted their target price on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. Weiss Ratings lowered Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $265.30.
Check Out Our Latest Stock Report on Johnson & Johnson
About Johnson & Johnson (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Further Reading Five stocks we like better than Johnson & Johnson Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBeacon Bank & Trust Sells 1,492 Shares of Microsoft Corporation $MSFT
NEXT HEADLINE »Microsoft Corporation $MSFT Shares Bought by Bogart Wealth LLC
Bessemer Group Inc. lessened its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 30.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 542,749 shares of the company’s stock after selling 232,372 shares during the period. Bessemer Group Inc.’s holdings in Johnson & Johnson were worth $132,670,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of JNJ. Greenberg Financial Group acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $954,000. World Investment Advisors boosted its position in shares of Johnson & Johnson by 19.6% in the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after purchasing an additional 26,450 shares during the period. Benchmark Financial LLC purchased a new position in Johnson & Johnson in the 4th quarter worth about $554,000. Sagespring Wealth Partners LLC raised its holdings in Johnson & Johnson by 6.2% during the 4th quarter. Sagespring Wealth Partners LLC now owns 45,222 shares of the company’s stock worth $9,359,000 after buying an additional 2,660 shares during the period. Finally, Robinhood Asset Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth about $11,853,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insider Activity In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.
Johnson & Johnson Stock Up 1.2% Shares of Johnson & Johnson stock opened at $252.93 on Friday. The stock has a 50-day simple moving average of $239.82 and a 200-day simple moving average of $234.63. Johnson & Johnson has a 52-week low of $162.78 and a 52-week high of $269.43. The firm has a market cap of $608.86 billion, a price-to-earnings ratio of 29.31, a P/E/G ratio of 2.39 and a beta of 0.24. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The company’s revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.68 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is currently 62.11%.
More Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Wall Street Analysts Forecast Growth Several brokerages have commented on JNJ. Scotiabank reiterated an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a report on Thursday. Guggenheim restated a “buy” rating and issued a $270.00 price target on shares of Johnson & Johnson in a research report on Friday. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday. HSBC set a $290.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, July 6th. Finally, Royal Bank Of Canada increased their target price on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $265.30.
View Our Latest Stock Report on JNJ
Johnson & Johnson Company Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Recommended Stories Five stocks we like better than Johnson & Johnson Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of New York Mellon Corp Has $224.87 Million Stock Holdings in CF Industries Holdings, Inc. $CF
NEXT HEADLINE »Dividend Assets Capital LLC Has $25.84 Million Holdings in Microsoft Corporation $MSFT
Financiere des Professionnels Fonds d investissement inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 19.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 46,180 shares of the company’s stock after selling 11,024 shares during the quarter. Johnson & Johnson comprises approximately 0.7% of Financiere des Professionnels Fonds d investissement inc.’s investment portfolio, making the stock its 29th biggest position. Financiere des Professionnels Fonds d investissement inc.’s holdings in Johnson & Johnson were worth $11,288,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Blueline Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson during the 4th quarter worth $26,000. DecisionPoint Financial LLC increased its holdings in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the period. Bay Harbor Wealth Management LLC increased its holdings in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the period. Finally, Family CFO Inc acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $31,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Johnson & Johnson In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.
Trending Headlines about Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Johnson & Johnson Price Performance JNJ stock opened at $252.93 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $608.86 billion, a P/E ratio of 29.31, a PEG ratio of 2.39 and a beta of 0.24. The business has a 50 day simple moving average of $239.82 and a 200-day simple moving average of $234.63. Johnson & Johnson has a twelve month low of $162.78 and a twelve month high of $269.43.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same period in the previous year, the company posted $2.77 EPS. The company’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.68 EPS for the current year.
Johnson & Johnson Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.
Wall Street Analysts Forecast Growth JNJ has been the subject of several recent research reports. Scotiabank reiterated an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday. Barclays raised their target price on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a report on Wednesday, May 13th. Finally, Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $265.30.
View Our Latest Analysis on JNJ
About Johnson & Johnson (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also Five stocks we like better than Johnson & Johnson Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAviance Capital Partners LLC Has $5.90 Million Holdings in Netflix, Inc. $NFLX
NEXT HEADLINE »Hamilton Point Investment Advisors LLC Raises Position in Johnson & Johnson $JNJ
Hamilton Point Investment Advisors LLC increased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 6.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 42,147 shares of the company’s stock after buying an additional 2,657 shares during the quarter. Johnson & Johnson comprises 1.6% of Hamilton Point Investment Advisors LLC’s portfolio, making the stock its 15th largest position. Hamilton Point Investment Advisors LLC’s holdings in Johnson & Johnson were worth $10,302,000 as of its most recent filing with the SEC.
Other hedge funds have also modified their holdings of the company. Blueline Advisors LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $25,000. Cresta Advisors Ltd. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $26,000. DecisionPoint Financial LLC lifted its position in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares in the last quarter. Family CFO Inc purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $31,000. Finally, Bay Harbor Wealth Management LLC grew its holdings in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after purchasing an additional 49 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Key Headlines Impacting Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Johnson & Johnson Stock Up 1.2% NYSE:JNJ opened at $252.93 on Friday. The company has a market capitalization of $608.86 billion, a price-to-earnings ratio of 29.31, a price-to-earnings-growth ratio of 2.39 and a beta of 0.24. Johnson & Johnson has a one year low of $162.78 and a one year high of $269.43. The stock has a 50-day simple moving average of $239.82 and a 200 day simple moving average of $234.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the prior year, the firm posted $2.77 earnings per share. Johnson & Johnson’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts predict that Johnson & Johnson will post 11.68 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 62.11%.
Insider Activity In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.
Analysts Set New Price Targets Several equities research analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $263.00 to $272.00 and gave the stock an “overweight” rating in a report on Thursday. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Johnson Rice upgraded Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 target price for the company in a research note on Thursday. Finally, Barclays raised their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $265.30.
Check Out Our Latest Stock Analysis on Johnson & Johnson
About Johnson & Johnson (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Stories Five stocks we like better than Johnson & Johnson Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFinanciere des Professionnels Fonds d investissement inc. Trims Stock Position in Johnson & Johnson $JNJ
NEXT HEADLINE »12,555 Shares in Johnson & Johnson $JNJ Acquired by Forty three Eighteen Advisors LLC
Forty three Eighteen Advisors LLC bought a new position in Johnson & Johnson (NYSE:JNJ – Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 12,555 shares of the company’s stock, valued at approximately $3,069,000. Johnson & Johnson accounts for about 2.3% of Forty three Eighteen Advisors LLC’s investment portfolio, making the stock its 11th largest position.
A number of other hedge funds have also added to or reduced their stakes in the stock. Auto Owners Insurance Co grew its holdings in shares of Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the period. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at $6,924,523,000. Capital World Investors bought a new position in Johnson & Johnson in the fourth quarter valued at about $2,005,942,000. Diamant Asset Management Inc. boosted its position in Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after purchasing an additional 4,454,778 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after purchasing an additional 3,731,074 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades Several equities research analysts have recently commented on JNJ shares. Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research report on Wednesday, April 15th. Barclays raised their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 15th. Argus boosted their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a report on Wednesday. Finally, JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $265.30.
Read Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Stock Performance Shares of JNJ opened at $252.93 on Friday. The business has a 50-day simple moving average of $239.82 and a two-hundred day simple moving average of $234.63. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 52 week low of $162.78 and a 52 week high of $269.43. The stock has a market cap of $608.86 billion, a price-to-earnings ratio of 29.31, a PEG ratio of 2.39 and a beta of 0.24.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts expect that Johnson & Johnson will post 11.68 EPS for the current year.
Johnson & Johnson Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is currently 62.11%.
Key Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson’s Earnings Dip Looks Like a Buying Opportunity Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here’s Why Insider Buying and Selling at Johnson & Johnson In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Profile (Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Recommended Stories Five stocks we like better than Johnson & Johnson Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEHamilton Point Investment Advisors LLC Raises Position in Johnson & Johnson $JNJ
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a stock built to be owned for decades, not traded, because its combination of an AAA-tier balance sheet, a 64-consecutive year dividend growth streak and a diversified healthcare franchise across pharmaceuticals and medical devices is engineered to compound quietly through every market cycle.
Johnson & Johnson is the kind of holding a retirement-focused investor can own and stop watching.
Pillar One: Durability of the Business JNJ operates across six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. Q1 2026 revenue reached $24.06 billion, up 9.9% year over year, with Innovative Medicine growing 11.2% and MedTech up 7.7%. Oncology drugs like DARZALEX ($3.96 billion, +22.5%) and TREMFYA (+68.3%) more than absorbed the 59.7% decline in STELARA from biosimilar competition. When your growth engines can eat a patent cliff and still deliver four consecutive EPS beats, the franchise is doing what a forever holding is supposed to do.
Pillar Two: Income Generation The board raised the quarterly dividend 3.1% to $1.34 per share in April 2026, extending the streak to 64 consecutive years. That places JNJ in the highest tier of Dividend Kings. The company generated $19.7 billion in free cash flow during full-year 2025, more than enough to fund the payout, buybacks, and pipeline investment simultaneously. For income investors looking at multi-decade holdings, the 24/7 Wall St. research team recently outlined the framework in its Never Touch the Principal report on forever dividend positions.
Pillar Three: Surviving the Cycles JNJ carries a beta of 0.235, meaning it moves a fraction of what the broader market does. Institutional ownership sits at 76.82%, and management raised full-year 2026 guidance to $100.3 billion to $101.3 billion in revenue with adjusted EPS of $11.45 to $11.65. Geographic balance ($13.33 billion U.S. and $10.73 billion Rest of World) further insulates the business from any single market shock.
Why JNJ Beats the Obvious Alternative The natural comparison is AbbVie (NYSE:ABBV), often paired with JNJ in dividend portfolios. AbbVie only began its independent dividend history after its 2013 spin-off from Abbott, a fraction of JNJ’s 64-year streak, and its post-Humira revenue base remains heavily dependent on Skyrizi and Rinvoq to replace a single lost blockbuster. JNJ’s revenue is spread across dozens of products spanning drugs and devices. Through the next several market cycles, patent expirations, and pricing regimes, the more diversified balance sheet is the safer permanent holding.
The Underperformance Scenario In risk-on, speculative growth markets, JNJ lags. A beta of 0.235 means it will not keep pace with high-beta names during a melt-up, and Q1 2026 included $330 million in litigation charges. That does not change the forever thesis. The right reason to own JNJ is to still be collecting a rising dividend in 2046, not to chase leadership in a bull run.
This is a long-term hold.
Want Up To $1,000? SoFi Is Giving New Active Invest Users Free StockLooking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts.
From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus.
July tests investor conviction. From the 2011 debt-ceiling standoff to the 2022 inflation shock, summer volatility has separated durable businesses from cyclical hopefuls. Three consumer staples and healthcare giants have paid and raised dividends through Black Monday 1987, the dot-com crash, the 2008 financial crisis, the COVID-19 shutdown and the 2022 bear market. Each is a Dividend King with a decades-long streak, and each delivered a beat-and-raise quarter heading into the back half of 2026.
This is the crisis-resilience watchlist for July 2026: three names that keep writing checks when the market stops working.
Coca-Cola (KO) Coca-Cola (NYSE:KO | KO Price Prediction) enters summer with momentum, with the stock up around 20% year to date as of July 17 along with a market cap near $361.09 billion. Q1 2026 reported April 28 delivering EPS of 86 cents versus the estimated 81 cents on revenue of $12.47 billion, up 12.1% year over year. That was the fourth consecutive EPS beat, with organic revenue up 10%, global unit case volume up 3% and Coca-Cola Zero Sugar volume up 13%. Operating margin expanded to 35.0% from 32.9%.
The bull case: pricing power, scale, and cash return. Management guided 2026 to 4-5% organic revenue growth, 8% to 9% comparable EPS growth, and roughly $12.2 billion in free cash flow. Coca-Cola paid $8.8 billion in dividends in 2025 and has raised the payout for 63 consecutive years. The quarterly dividend stepped to 53 cents in 2026 from 51 cents in 2025. KO raised its quarterly payout to 41 cents in 2009 from 38 cents in 2008, straight through the financial crisis. CEO Henrique Braun said: “We’ve had a strong start to the year. Our performance this quarter reflects our unwavering focus on staying close to the consumer, executing locally and managing complexity.”
Risk to watch for: the pending Coca-Cola Beverages Africa sale, ongoing IRS tax litigation and a roughly 4% headwind from acquisitions and divestitures. Shares trade at a P/E of 28, not cheap for a mid-single-digit growth business.
Johnson & Johnson (JNJ) Johnson & Johnson (NYSE:JNJ) has been one of the year’s biggest large-cap surprises, up 22.41% year to date and 55.74% over the past year. Q1 2026 reported April 14 posting adjusted EPS of $2.70 versus $2.68 expected on revenue of $24.06 billion, up 9.9% year over year. Innovative Medicine came in at $15.43 billion, up 11.2%, with DARZALEX at $3.96 billion (+22.5%), TREMFYA at $1.61 billion (+68.3%) and CARVYKTI at $597 million (+62.1%).
The dividend track record is the point. JNJ raised its Q2 2026 dividend 3.1% to $1.34 per share, extending the streak to 64 consecutive years of increases. The company kept raising the payout through the COVID-19 crash, moving from $0.95 in Q1 2020 to $1.01 in Q2 2020. Management raised 2026 guidance to revenue of $100.3 billion to $101.3 billion and adjusted EPS of $11.45 to $11.65. CEO Joaquin Duato said: “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact.” Composite prediction-market sentiment sits at 60.67, bullish with medium confidence.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.
Risk to watch for: STELARA biosimilar erosion drove that franchise down 59.7% to $656 million in Q1, litigation charges added $330 million in the quarter, and the planned Orthopaedics separation introduces execution risk. For income investors weighing multi-decade streaks, our 10 Dividend Kings research walks through how these compounders behave across full market cycles.
Procter & Gamble (PG) Procter & Gamble (NYSE:PG) is the least exciting name on this list, and that is the point. Fiscal Q3 2026 reported April 24 producing core EPS of $1.59 versus $1.56 estimated on net sales of $21.24 billion, up 7.4% year over year. Organic sales rose 3%, Beauty jumped 7% organic and growth was broad across all five segments. That makes four straight quarters of top- and bottom-line beats.
The dividend streak stands at 70 consecutive annual increases and 136 consecutive years of dividend payments since incorporation in 1890. The Q2 2026 payout was raised to $1.0885 per quarter from $1.0568. FY2026 plans include roughly $10 billion in dividends and about $5 billion in share repurchases. Beta of 0.38 makes PG one of the lowest-volatility large caps in the S&P 500. Reddit sentiment reads bullish at 72, with a composite score of 67.15. CEO Shailesh Jejurikar said the quarter delivered “a solid acceleration in top-line results in our fiscal third quarter, with broad-based growth across product categories and regions.”
Risk to watch for: P&G expects FY2026 core EPS to land toward the lower end of its $6.83 to $7.09 range due to roughly $400 million in after-tax tariff costs and a $150 million commodity headwind. Core gross margin slipped 100 basis points. Shares are up just 5.03% year to date, but that muted move is what defensive investors want when volatility strikes.
What to Watch Next All three cleared Q1 with beats, raised dividends in 2026, and carry crisis track records predating most current Wall Street portfolio managers. If July delivers another volatility shock, keep an eye on these three: History says the checks keep clearing regardless of headlines.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.
Key Takeaways JNJ shares fell after Q2 results despite earnings and sales beating estimates and a higher 2026 guidance.Johnson & Johnson's MedTech missed expectations as Cardiovascular and Abiomed weighed on growth.JNJ expects better second-half MedTech growth, led by Vision, Orthopedics and Surgery. Johnson & Johnson's (JNJ - Free Report) shares have declined 1.5% since it reported second-quarter 2026 results on July 15.
J&J beat estimates for both earnings and sales in the second quarter. While earnings rose 4.7%, sales rose 6.6% from the year-ago period. Backed by a strong second-quarter performance and uptake of new products, J&J raised its 2026 sales and earnings guidance for the year. However, its shares declined despite the beat-and-raise performance as its MedTech unit underperformed expectations. While sales in its Innovative Medicine segment remain strong and are the primary driver of top-line growth, its soft MedTech growth was the primary factor that led the shares to decline.
Let's discuss what went wrong at MedTech in the second quarter.
What Caused J&J’s MedTech Unit to Underperform in Q2?J&J’s MedTech sales increased 4.5% to $8.93 billion in the second quarter, including operational growth of 3.6%. However, MedTech segment sales slightly missed the Zacks Consensus Estimate of $8.96 billion. MedTech segment sales were mainly hurt by the soft performance of its Cardiovascular business.
Cardiovascular sales rose 3.1% on an operational basis. However, the growth was slower than prior trends due to competitive pressure in the electrophysiology business and a decline in Abiomed sales, partially offset by continued double-digit growth in Shockwave.
Electrophysiology sales increased 3.1% as procedure growth, commercial execution and contribution from new products were partially offset by competitive PFA pressures and negative impact from China inventory dynamics.
Abiomed sales declined 2% in the second quarter as procedure volumes slowed due to changes in Impella usage patterns. The slowdown followed a recent U.K. clinical trial that questioned the benefit of Impella devices in certain high-risk procedures, prompting physicians to reassess patient selection and adopt a more cautious approach to using the device. However, Abiomed sales in outside U.S. markets remained strong.
J&J believes this is a temporary issue and is working with physicians to ensure the device is used in the right patients based on its existing clinical evidence.
Reflecting these challenges, J&J tempered its outlook for Abiomed, now expecting only modest growth in the second half of 2026 rather than the stronger rebound it had previously anticipated. The impact of the U.K. study is expected to linger and impact Abiomed’s growth until the PROTECT IV data is presented in 2027. PROTECT IV is a large clinical trial of the company’s Impella device in high-risk percutaneous coronary intervention (PCI).
Will J&J’s MedTech Sales Recover From Here?On the conference call, J&J clarified that while its Cardiovascular sales slowed down in the second quarter, its other three businesses, Surgery, Vision and Orthopedics all accelerated in the quarter and performed above expectations. J&J claimed that overall procedure volumes were stable and there was no broad-based slowdown in medical procedure volumes across its MedTech business.
J&J clarified that although some large U.S. hospitals have reported weaker volumes for certain elective procedures, those trends are not reflected in its own business. J&J also said that the expiration of Affordable Care Act (ACA) subsidies has not had any meaningful impact on procedure volumes so far and is unlikely to materially affect MedTech demand.
J&J expects MedTech growth to improve in the second half, driven by strength in Vision, Orthopedics, Surgery and better performance in Cardiovascular.
Overall, J&J’s second -quarter results were strong. Although the MedTech business experienced temporary weakness, management remains confident that growth will improve in the second half. Meanwhile, the Innovative Medicine segment continues to exhibit robust underlying fundamentals, supported by sustained demand for its growth portfolio and a promising outlook.
J&J’s Key Competitors in the Medical Devices MarketJ&J’s MedTech unit faces strong competition from several major players in the medical device industry, like Medtronic (MDT - Free Report) , Abbott, Stryker (SYK - Free Report) and Boston Scientific (BSX - Free Report) .
While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker is a major player in orthopedics and surgical equipment. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics and diabetes care.
JNJ’s Price Performance, Valuation and EstimatesJ&J’s shares have outperformed the industry so far this year. The stock has risen 22.1% this year compared with 10.2% appreciation of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 20.58 forward earnings, higher than 18.46 for the industry. The stock is also trading above its five-year mean of 15.65.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $11.59 per share to $11.61 per share over the past seven days, while that for 2027 earnings has gone up from $12.66 per share to $12.67 over the same time frame.
Image Source: Zacks Investment Research
J&J has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Johnson & Johnson posted strong Q2 earnings. Sales of its NMDA receptor antagonist, called Spravato, for the treatment of depression, rose 41.1% year-on-year to $584 million in Q2. Also, J&J raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75.
• Johnson & Johnson stock is trading at elevated levels. What’s next for JNJ stock?
With ex-Stelara growth of more than 14% year-on-year and eight brands delivering double-digit growth in the second quarter, the company’s Innovative Medicine (IM) momentum is "building into 2027, according to RBC Capital Markets.
The Johnson & Johnson Analyst: Analyst Shagun Singh maintained an Outperform rating and price target of $287.
The Johnson & Johnson Thesis: The company delivered better-than-expected sales and earnings, driven by IM strength, while MedTech missed on cardio weakness, Singh said in the note.
Check out other analyst stock ratings.
Johnson & Johnson delivered another quarter of mid-teens ex-Stelara IM growth, he added.
Stelara now contributes only 4% of IM sales, while the remaining 96% grew more than 14% year-on-year in the quarter, "highlighting the durability of JNJ’s growth engine," the analyst stated.
He highlighted:
Icotyde reached 11,000 patients Tremfya delivered its first quarter of $2 billion in sales, up 71% year-on-year Tecvayli sales grew 56% year-on-year INLEXZO’s new patient insertions rose 75% sequentially, outperforming all recent competitive launches "We believe the breadth of IM’s launch portfolio provides strong visibility into 2027+ acceleration and supports JNJ’s path to becoming the number one oncology company by 2030 as well as progress towards double-digit growth by decade’s end," Singh wrote.
While the stock declined following the earnings release due to the underperformance of MedTech, this business is positioned for a recovery in the back half of 2026, "with three of four businesses accelerating in Q2’26 and procedure volumes intact," he further stated.
JNJ Price Action: Shares of Johnson & Johnson had risen by 0.84% to $249.09 at the time of publication on Thursday.
Market News and Data brought to you by Benzinga APIs
Key Takeaways Johnson & Johnson beat Q2 earnings and revenue estimates and raised its 2026 sales and EPS outlook.JNJ expects to surpass $100 billion in annual revenues, supported by Innovative Medicine momentum.Johnson & Johnson said new launches and pipeline progress offset STELARA pressure and MedTech headwinds. Johnson & Johnson (JNJ - Free Report) delivered better-than-expected second-quarter 2026 results, supported by continued strength across its Innovative Medicine portfolio and steady MedTech execution. The healthcare giant reported adjusted earnings and revenues ahead of consensus estimates while lifting its full-year sales and earnings outlook, reflecting confidence in its commercial momentum and expanding pipeline.
Management emphasized that the company remains on track to surpass $100 billion in annual revenues for the first time in its 140-year history. Strong performances from oncology, immunology and neuroscience products, coupled with a growing roster of new launches, more than offset continued pressure from STELARA biosimilar competition and softer trends in portions of the MedTech business.
Earnings Beat ExpectationsJohnson & Johnson reported second-quarter adjusted earnings of $2.90 per share, topping the Zacks Consensus Estimate of $2.84. Revenues increased 6.6% year over year to $25.31 billion, outpacing the Zacks Consensus Estimate of $25.18 billion.
Reported EPS was $2.27 compared with $2.29 in the year-ago period, while adjusted net earnings rose 5.7% to $7.08 billion. Worldwide operational sales increased 5.6%, or 5.7% on an adjusted operational basis.
Innovative Medicine Continues to Drive GrowthInnovative Medicine remained the primary growth engine, with worldwide sales climbing 7.8% (6.8% operational) to $16.38 billion. Growth was led by blockbuster oncology therapies DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE, alongside continued momentum from TREMFYA, SPRAVATO and CAPLYTA.
Management noted that excluding STELARA, whose sales continue to be pressured by biosimilar competition, the company delivered double-digit operational growth during the quarter. CEO Joaquin Duato said Johnson & Johnson now has 28 platforms generating more than $1 billion in annual sales and expects new launches such as ICOTYDE, INLEXZO and RYBREVANT to support accelerating growth into 2027.
TREMFYA remained a standout performer as inflammatory bowel disease indications continued driving strong uptake. Meanwhile, CAPLYTA benefited from its recently expanded schizophrenia label, while SPRAVATO maintained robust demand.
MedTech Performance Mixed but Long-Term Outlook IntactMedTech revenues increased 4.5% (3.6% operational) to $8.93 billion.
Growth was driven by cardiovascular products, wound closure and biosurgery offerings, contact lenses and orthopedic trauma products. Shockwave continued generating double-digit growth, while the Vision business benefited from strong ACUVUE demand and premium intraocular lens adoption.
However, management acknowledged weaker-than-expected performance in Heart Recovery, where increased physician caution following external clinical data temporarily pressured Abiomed procedure volumes. CFO Joseph Wolk said expectations for Abiomed have been moderated for the remainder of 2026, though the company continues to expect improvement over the longer term.
Pipeline Momentum Supports Long-Term GrowthExecutives highlighted another active quarter across the pipeline, including FDA approvals for TREMFYA's psoriatic arthritis label expansion, CAPLYTA for relapse prevention in schizophrenia and the Dual Energy THERMOCOOL SMARTTOUCH SF platform.
The company also reported encouraging clinical data for RYBREVANT FASPRO in head and neck cancer, TALVEY plus DARZALEX FASPRO in multiple myeloma and the OTTAVA robotic surgery platform.
Management reiterated confidence that recent launches are tracking ahead of expectations. ICOTYDE has already reached more than 10,000 patient starts, with executives describing physician uptake and payer access as stronger than initially anticipated.
Johnson & Johnson Raises 2026 GuidanceFollowing the stronger-than-expected first half, Johnson & Johnson increased its 2026 outlook.
The company now expects reported sales of $100.8-$101.4 billion, representing approximately 7.3% growth at the midpoint. Adjusted EPS guidance was raised to $11.60-$11.75, with a midpoint of $11.68, up $0.13 from the prior guidance.
Management also raised adjusted operational EPS guidance to a midpoint of $11.58 while expecting approximately 75 basis points of adjusted pretax operating margin expansion during the year.
Analyst Questions Focus on Growth SustainabilityDuring the Q&A session, analysts concentrated on the drivers behind the guidance increase, launch trajectories for ICOTYDE, MedTech recovery prospects and pipeline execution.
Management indicated that Innovative Medicine will contribute the majority of the higher revenue outlook, supported by continued momentum from TREMFYA, ICOTYDE, INLEXZO and oncology products. While MedTech growth is expected to improve during the second half, executives acknowledged that Abiomed's recovery will likely extend into 2027.
Executives also emphasized upcoming catalysts, including additional data readouts across oncology and immunology, potential FDA approval for IMAAVY in warm autoimmune hemolytic anemia and anticipated regulatory milestones for the OTTAVA robotic surgical system.
Looking AheadJohnson & Johnson exited the quarter with broad-based commercial momentum, multiple successful product launches and improving financial guidance. Although biosimilar pressure on STELARA and temporary MedTech headwinds remain challenges, management believes the breadth of its portfolio and pipeline positions the company for sustained long-term growth while maintaining its goal of reaching double-digit growth by the end of the decade.
Zacks Rank and Style Scores SignalsJohnson & Johnson currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock has a Value Score of C, a Growth Score of F and a Momentum Score of A, resulting in a VGM Score of D. Investors following the Zacks Style Scores may find the company's strong momentum profile encouraging, though the lower Growth and VGM scores suggest a more balanced risk-reward profile following the recent earnings report.
RAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes' Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment. Expanding Innovations (EI) is a commercial-stage medical technology company focused on developing and commercializing.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all. Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson.
On Wednesday morning, Johnson & Johnson (NYSE:JNJ) published its second-quarter earnings report, but this wasn't greeted warmly. Investors generally sold the stock, and by the end of that trading session, it was down by almost 3%.
This occurred on a broadly positive day for the stock market, with the bellwether S&P 500 index closing in positive territory. What did those selling investors find so unappealing about the pharmaceutical giant's figures, and was that reaction justified? Let's explore.
Image source: The Motley Fool.
Slightly better than expected Perhaps the first source of discontent for Mr. Market is that, while Johnson & Johnson notched a double beat on analyst estimates, neither beat was crushing.
In the quarter, the company's total sales were a shade over $25.3 billion, which bettered the same period of 2025 by almost 7%. Yet they weren't vastly higher than the consensus pundit projection of $25 billion.
As for profitability, the dynamic was similar. Net income not under generally accepted accounting principles (non-GAAP, or adjusted) rose at a nearly 6% clip to $7.08 billion, or $2.90 per share. That was a few cents higher than the average analyst estimate of $2.86.
Johnson & Johnson is essentially two healthcare businesses in one: a massive pharmaceutical company and an important, influential medical device unit.
Of the pair, the former (officially known as "innovative medicine") is the larger; it brought in nearly $16.4 billion during the quarter, for a year-over-year improvement of almost 8%. Devices, or "MedTech," as the company calls this unit, saw a more modest lift of under 5% to slightly more than $8.9 billion.
Breaking down those results further, in the drug sphere, Johnson & Johnson did particularly well, with immunology drug Tremfya's sales growing a very robust 73% to $2 billion. This success is critical for the company as that medicine supplants an older immunology treatment, Stelara. The latter's sales are sliding rapidly, with a 56% decline (to $740 million) in the quarter.
Meanwhile, the company's oncology portfolio -- one of the strongest in the industry -- was looking robust. Its star drug in that lineup, blood cancer treatment Darzalex, posted a nearly 19% lift in sales to over $4.2 billion. Overall, the portfolio's sales rose by 17% to $7.4 billion.
As for medical devices, the overall growth in that business was overshadowed by a slump in one product line, Abiomed. This comprises the Impella small-form heart pumps, whose sales slid by 2% to $440 million. That was in marked contrast to the previous quarter, where Abiomed sales increased by 16%.
That wasn't necessarily a shocking development, as the results of a U.K. study published in late March in the always-influential New England Journal of Medicine indicated that Impellas might not be as suitable or beneficial for some high-risk coronary interventions as believed.
That sudden second-quarter decline in sales of those products suggests doctors might be concerned about the findings. And that Johnson & Johnson might not be doing enough to put them more at ease.
Today's Change
(
-2.69
%) $
-6.83
Current Price
$
247.02
Boosting where it counts Nevertheless, Johnson & Johnson sounded a quite robust note about its trailing performance and its near future. It quoted CEO Joaquin Duato as saying that the quarter highlighted "the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world's toughest health challenges."
It's clearly more confident it'll play a crucial role in this, as it raised its guidance for all of 2026. Headline sales should come in at $100.8 billion to $101.4 billion; the previous forecast was $100.3 billion to $101.3 billion. Adjusted earnings per share (EPS) are estimated at $11.60 to $11.75 for the year. That supplants the former guidance range of $11.45 to $11.65.
To me, while Johnson & Johnson's second quarter wasn't the disappointment indicated by that Wednesday sell-off, it wasn't a blowout either. I think the company is doing well, but investors might be looking elsewhere since other major pharmaceuticals have delivered more impressive growth.
I'm bullish on this one's future, though, so I think the post-earnings slump makes it something of a bargain buy.
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression treatment, with Jefferies writing that the drug's commercial performance supports the long-term market opportunity for the sector.
Johnson & Johnson (NYSE:JNJ) reported worldwide second-quarter Spravato (esketamine nasal spray) sales of $584 million, up 25% from the first quarter, including US sales of $514 million. Jefferies wrote that the figures imply an annualized revenue run rate of more than $2.3 billion and keep the product on track to reach the company's previously guided annual sales of $3 billion to $3.5 billion by 2027-2028.
The analysts wrote that Spravato's momentum in treatment-resistant depression and major depressive disorder with suicidal ideation "supports the notion psychedelics can be commercially viable in hard-to-treat mental health disorders," citing Johnson & Johnson's investment in treatment sites, physician education and reimbursement.
Jefferies noted that Johnson & Johnson has guided for Spravato peak annual sales of up to $5 billion and estimated that more than 250,000 patients worldwide may have been treated with the therapy cumulatively.
The firm also pointed to increasing investor interest in psychedelic medicines following positive mid- and late-stage clinical trial data across depression, anxiety and post-traumatic stress disorder, alongside what it described as an improving regulatory backdrop and growing interest from large pharmaceutical companies.
Jefferies highlighted several upcoming milestones across the sector, including Compass Pathways (NASDAQ:CMPS)' planned rolling New Drug Application completion for COMP360 in the fourth quarter of 2026, which could support a potential approval by year-end and a commercial launch in the first half of 2027.
The analysts also pointed to AtaiBeckley’s Phase III program for BPL-003 in treatment-resistant depression, expected to generate data in early 2029, and upcoming Phase II data for VLS-01 later this year..
Jefferies added that Johnson & Johnson's network of approximately 7,000 to 8,000 US treatment sites could help facilitate future adoption of psychedelic therapies, noting that Atai's intranasal BPL-003 could fit within the same two-hour treatment framework currently used for Spravato.
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression treatment, with Jefferies writing that the drug's commercial performance supports the long-term market opportunity for the sector.
Johnson & Johnson (NYSE:JNJ) reported worldwide second-quarter Spravato (esketamine nasal spray) sales of $584 million, up 25% from the first quarter, including US sales of $514 million. Jefferies wrote that the figures imply an annualized revenue run rate of more than $2.3 billion and keep the product on track to reach the company's previously guided annual sales of $3 billion to $3.5 billion by 2027-2028.
The analysts wrote that Spravato's momentum in treatment-resistant depression and major depressive disorder with suicidal ideation "supports the notion psychedelics can be commercially viable in hard-to-treat mental health disorders," citing Johnson & Johnson's investment in treatment sites, physician education and reimbursement.
Jefferies noted that Johnson & Johnson has guided for Spravato peak annual sales of up to $5 billion and estimated that more than 250,000 patients worldwide may have been treated with the therapy cumulatively.
The firm also pointed to increasing investor interest in psychedelic medicines following positive mid- and late-stage clinical trial data across depression, anxiety and post-traumatic stress disorder, alongside what it described as an improving regulatory backdrop and growing interest from large pharmaceutical companies.
Jefferies highlighted several upcoming milestones across the sector, including Compass Pathways (NASDAQ:CMPS)' planned rolling New Drug Application completion for COMP360 in the fourth quarter of 2026, which could support a potential approval by year-end and a commercial launch in the first half of 2027.
The analysts also pointed to AtaiBeckley’s Phase III program for BPL-003 in treatment-resistant depression, expected to generate data in early 2029, and upcoming Phase II data for VLS-01 later this year..
Jefferies added that Johnson & Johnson's network of approximately 7,000 to 8,000 US treatment sites could help facilitate future adoption of psychedelic therapies, noting that Atai's intranasal BPL-003 could fit within the same two-hour treatment framework currently used for Spravato.
Tech analyst Dan Ives announced that he has teamed up with Yorkville Securities to form a new kind of merchant bank. Johnson & Johnson (JNJ) beat Q2 estimates and raised guidance, but EPS decline weighed on sentiment despite innovative medicine strength.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is up 24.03% year to date and 65.92% over the past year, riding oncology strength and a raised full-year outlook. Our proprietary model sees room to run.
Our 24/7 Wall St. price target for JNJ is $277.85, implying 9.45% upside from the current $253.85. The recommendation is buy with 90% confidence, high by our standards for a mega-cap.
24/7 Wall St. Price Target Summary Metric Value Current Price $253.85 24/7 Wall St. Price Target $277.85 Upside 9.45% Recommendation BUY Confidence Level 90% A Year of Accelerated Growth Is Playing Out JNJ delivered Q1 2026 revenue of $24.06 billion, up 9.9% year over year, with adjusted EPS of $2.70 beating the $2.6773 consensus. Q2 2026 reinforced the trajectory with reported sales of $25.3 billion (up 6.6%) and adjusted EPS of $2.90, prompting another guidance raise.
Management now targets full-year revenue of $100.30 billion to $101.30 billion and adjusted EPS of $11.45 to $11.65. The stock traded as low as $155.89 in the past 52 weeks and now sits just below its $269.43 high after a 5.01% pullback in the last week.
Why Bulls See a Breakout Above $290 Oncology remains the engine. DARZALEX grew 22.5% to $3.96 billion in Q1, TREMFYA surged 68.3%, CARVYKTI jumped 62.1%, and RYBREVANT/LAZCLUZE climbed 82.7%. Recent approvals for ICOTYDE, VARIPULSE Pro, and TECVAYLI plus DARZALEX FASPRO extend the runway.
Management committed to double-digit growth by decade’s end, and the planned Orthopaedics separation could unlock a valuation re-rating. Our bull case price target over the next 12 months is $290.54, a 14.45% total return.
What Could Go Wrong STELARA collapsed 59.7% to $656 million as biosimilar competition intensified, and litigation charges of $330 million weighed on GAAP net income, which fell 52.4%.
July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.
Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.
With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.
Bulls view the decline as optics driven by TREMFYA absorbing STELARA share, with the litigation charge running as a non-recurring item. Our bear case target is $236.59, a 6.8% drawdown if patent cliffs bite harder than expected.
How JNJ Compares to Merck and Pfizer Merck (NYSE:MRK) is the closest oncology-driven comp given KEYTRUDA’s dominance. Merck guides 2026 non-GAAP EPS of $8.93-$9.03 on revenue of $64.3B-$64.8B, but a $0.37 Cidara acquisition charge muddies the trailing picture. JNJ’s diversified MedTech plus Innovative Medicine mix looks cleaner, supporting our target’s forward P/E of roughly 23.
Pfizer (NYSE:PFE) trades at a trailing P/E of just 14 with a dividend yield near 6%, versus JNJ’s 30 P/E and 2.01% yield. Pfizer looks statistically cheaper, but the discount reflects post-COVID revenue erosion and patent-cliff risk. JNJ’s premium is earned, and our target leaves room versus the sell-side consensus of $259.
I’d Buy It Here The 24/7 Wall St. price target of $277.85 with 90% confidence and a buy rating reflects a company hitting on innovation while paying investors to wait through a 64th consecutive dividend increase.
I’d be a buyer if the December 8 Enterprise Business Review confirms the double-digit growth path. I’d stay sidelined if litigation charges reaccelerate or if the Orthopaedics separation gets delayed.
Year 24/7 Wall St. Price Target 2026 $277.85 2027 $298.00 2028 $318.00 2029 $337.00 2030 $356.79 These projections assume JNJ executes on its path toward double-digit growth by decade’s end. Significant upside or downside could result from oncology pipeline outcomes or the Orthopaedics separation.
Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.
Over 50,000 people already have, along with global giants like General Motors and POSCO.
Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.
This is a fair market value price provided by Massive. Learn more.
52-Week Range$159.80▼
$269.43Dividend Yield2.15%
P/E Ratio28.78
Price Target$261.26
Johnson & Johnson NYSE: JNJ is an elite income investment because of its Dividend King status, healthy balance sheet, and incredibly strong, defensive business model. Critical details include its product portfolio and pipeline, which are producing numerous catalysts simultaneously in 2026.
A wave of approvals, expanded uses, and pipeline advances promises sustained growth, robust cash flow, and capital return safety long into the future. Which is why the mid-July price pullback, triggered by the earnings results and guidance, is a textbook entry point.
Get Johnson & Johnson alerts:
JNJ Pulls Back to Buy ZoneJNJ hit a peak ahead of the earnings release, indicating potential for a pullback. Down approximately 2% following the release, the stock is on track for a nearly-10% pullback, which would represent a significant discount relative to the recent high, but lower lows are unlikely.
Likely buyers on the dip include the institutional group, which owns more than 60% of the stock and has been accumulating, and the analysts, whose trends reflect increasing confidence in an already fundamentally stable company.
Analyst trends include increased coverage versus last year, firmer sentiment, a 74% Buy-side bias to the Moderate Buy rating, and an uptrend in the price targets. Consensus is a sticking point, with fair value near the early-July highs, but the trend matters, leading to the high end of $300 and fresh all-time highs. A move to fresh all-time highs is significant for chart watchers, as it would indicate a continuation of the trend, with near-term targets at $300 and longer-term targets in the $350 region.
Analyst chatter following the release focused on the beat relative to the high bar set. Strength in the pharmaceutical pipeline and fundamental health in MedTech were also noted. Importantly, the market views JNJ as having successfully moved past its patent cliff, on track for sustainable growth, cash flow, and capital returns.
Capital returns include buybacks, but they are opportunistic and often insufficient to offset dilutive activity; the dividend is much more significant. The dividend yields an above-average 2.1% and has grown at a mid-single-digit compound annual growth rate in recent years. The likely outcome is that JNJ will continue with annual increases well into the future.
Johnson & Johnson’s Strength Driven by Diversified PortfolioJohnson & Johnson had a strong quarter, revealing the strength of its repositioning efforts and portfolio. The company’s $25.31 billion in net revenue was up 6.8% year-over-year (YOY), 100 basis points (bps) better than expected, on strength in U.S. and International markets across the Innovative Medicine and MedTech portfolios. There were spotty weaknesses within each segment tied to legacy products, but each was offset by a strength. Critical details include the half-dozen new approvals and a dozen or so positive pipeline updates.
Margin news was also good. The company experienced margin pressures but was able to offset them to a large degree. Bottom-line results include $2.90 in adjusted earnings per share (EPS), up 4.7% YOY and a nickel ahead of consensus, and $8.7 billion in free cash flow (FCF), more than sufficient to support balance sheet health while investing and returning capital to investors.
Looking ahead, the company expects the strengths to continue and has raised guidance accordingly. The new full-year targets were increased by 30 bps at the midpoint, expecting 7.3% top-line growth and $11.68 in adjusted earnings, well above the consensus estimate. Among the factors investors should consider is that JNJ expects revenue to surpass the $100 billion mark for the first time in its history, a psychological threshold for institutional investors.
JNJ: Low Risk, High RewardJohnson & Johnson’s primary risks include its patent cliff and ongoing talc litigation. The talc litigation refers to decades of lawsuits alleging that the company's talc-based products—most notably its baby powder were contaminated with asbestos and caused ovarian cancer and mesothelioma.
The patent cliff appears to be mitigated, with approvals and pipeline gaining momentum, leaving talc as the primary hurdle for investors. The company continues to face thousands of individual claims despite its attempts to settle. This leaves it open to cash-draining adverse decisions that can drain investment capital and capacity for capital returns. What the market gets wrong is that talc isn’t a company-ending threat but rather a slow drain on capital that may or may not worsen.
Catalysts include the planned spin-off of the company's orthopedics business. Analysts view it as a price-multiple unlocking move, trimming lower-margin, lower-growth businesses in favor of higher-performing ones. The resulting company will be a pharma and medtech powerhouse with strong franchises in oncology, cardiology, and potentially robotics. The OTTAVA robotic system is on track for approval as soon as later this year, setting the stage for it to gain share versus competitors like Intuitive Surgical NASDAQ: ISRG.
Should You Invest $1,000 in Johnson & Johnson Right Now?Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Walmart (NYSE:WMT | WMT Price Prediction) and Johnson & Johnson (NYSE:JNJ) just delivered results that show two defensive giants pulling on very different levers.
Walmart posted $175.68 billion in Q1 FY27 revenue with omnichannel firing on all cylinders. J&J leaned on its pharma pipeline to grow Q1 2026 sales 9.9%. Both beat estimates. The playbooks could hardly look more different.
Retail Flywheel Meets Pharma Firepower Walmart’s quarter was a story of stickiness turning into leverage. U.S. comp sales rose 4.1% ex-fuel on 3.0% transaction growth, and global eCommerce jumped 26%, now 23% of sales. Advertising climbed 37%, and marketplace sales surged nearly 50%, the best in ten quarters.
Upper-income households keep trading in, and CEO John Furner credited “innovative technologies, driving productivity through automation, and growing higher-margin commerce solutions.” Free cash flow turned negative at -$1.95 billion as capex jumped 34%. That signals investment in future throughput capacity.
J&J’s engine ran on drugs. Innovative Medicine rose 11.2% to $15.43 billion, with DARZALEX at $3.96 billion (+22.5%) and TREMFYA up 68.3%, absorbing the STELARA biosimilar shock. MedTech added 7.7%, led by cardiovascular. CEO Joaquin Duato called the pipeline “unrivaled,” pointing to fresh approvals like ICOTYDE and VARIPULSE Pro.
One Widens The Store. One Prunes The Portfolio. Lens Walmart J&J Core Bet Omnichannel + ads Oncology and immunology drugs Growth Engine eCommerce +26% TREMFYA +68.3% Key Vulnerability Tariffs, fuel (250 bps hit) STELARA erosion (-59.7%) Capital Move New $30B buyback 64th straight dividend hike Walmart is widening: more delivery, more marketplace sellers, more ad inventory through VIZIO.
J&J is narrowing, planning a DePuy Synthes orthopaedics spinoff within 18 to 24 months and pouring over $1 billion into cell therapy manufacturing. Different visions of defense.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Walmart didn't make the cut. Grab the names FREE today.
The Next Test Is Whether Consumers Hold Up With University of Michigan consumer sentiment at 44.8, near recessionary territory, I want to see whether Walmart’s upper-income share gains survive a broader pullback.
J&J faces a nearer catalyst: prediction markets currently price a 92.5% probability of a Q2 EPS beat, with Innovative Medicine consensus clustering around $16.2 to $16.65 billion. Guidance was already raised to $11.45 to $11.65 adjusted EPS for the year.
Why I Lean Toward J&J At These Prices Both are quality. You are paying very differently for them.
Walmart trades at a trailing P/E of 40 with a 0.85% yield, while J&J sits near 30 with a 2.01% yield and 21.8% profit margins versus Walmart’s 3.14%.
J&J shares are already up 25.56% year to date, and I still find the pipeline math more compelling than paying 39 times forward earnings for a retailer with negative free cash flow this quarter. Walmart offers brand-driven compounding for investors patient with tariff noise. J&J’s combination of yield, margins, and pipeline stands out at these valuations.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Walmart didn't make the cut. Grab the names FREE today.
This Dividend ETF Choice Could Shape Your Income Strategy Through 2026Johnson & Johnson NYSE: JNJ raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.
Chairman and Chief Executive Officer Joaquin Duato said the company delivered a “Q2 beat on the top and bottom line and raised guidance,” describing 2026 as a year of accelerated growth for Johnson & Johnson. The company reported worldwide quarterly sales of $25.3 billion, up 5.6% operationally. Excluding STELARA, Duato said Johnson & Johnson grew double digits in the quarter.
Get Johnson & Johnson alerts:
3 Stocks Doing the Heavy Lifting in Healthcare’s ReboundRyan Kurz, Vice President of Investor Relations, said U.S. sales rose 7.3%, while sales outside the U.S. increased 3.4%. Net earnings were $5.5 billion, and diluted earnings per share were $2.27, compared with $2.29 a year earlier. Adjusted net earnings were $7.1 billion, with adjusted diluted EPS of $2.90, up 4.7% from the second quarter of 2025.
Innovative Medicine Leads Growth Innovative Medicine sales totaled $16.4 billion, up 6.8% operationally, despite what Kurz described as an approximately 760-basis-point headwind from STELARA. The division posted 8.9% growth in the U.S. and 3.6% growth outside the U.S.
3 Dividend Kings That Earn Their Crown Every QuarterDuato said the Innovative Medicine business had eight brands growing double digits. In oncology, DARZALEX remained the company’s largest product, with quarterly sales of more than $4 billion and growth of 17.6%, driven by share gains and market growth in multiple myeloma. CARVYKTI grew 47.7%, TECVAYLI grew 56.1% and TALVEY grew 62.6%.
In lung cancer, RYBREVANT plus LAZCLUZE grew 61.6%, supported by launch uptake across regions and share gains in first- and second-line settings. ERLEADA grew 7.6% in prostate cancer, with share gains and market growth partly offset by unfavorable patient mix and inventory dynamics.
In immunology, TREMFYA delivered 71% growth. Duato said it remains the fastest-growing advanced therapy in both Crohn’s disease and ulcerative colitis. STELARA declined 55.7%, reflecting biosimilar competition, adoption of newer treatment classes and unfavorable patient mix.
Jennifer Taubert, Executive Vice President and Worldwide Chairman, Innovative Medicine, said during the question-and-answer session that TREMFYA reached its first $2 billion quarter. She said the product is leading new patient starts, or induction share, among IL-23 therapies in both ulcerative colitis and Crohn’s disease.
Launches Gain Traction Management highlighted early momentum for ICOTYDE, INLEXZO and other newer products. Duato said more than 10,000 patients had initiated therapy on ICOTYDE since launch, citing demand for a once-daily oral psoriasis treatment. In the Q&A, Taubert updated that figure to 11,000 patients, with more than 18,000 prescriptions written and 6,000 unique prescribers. She said commercial coverage had surpassed 50% within 90 days, ahead of company projections.
Taubert said ICOTYDE is being positioned as a first-choice systemic treatment for psoriasis patients moving beyond topical therapy, while TREMFYA is being positioned as a first-choice biologic, particularly for patients with or at risk of psoriatic arthritis. John Reed, Executive Vice President, Innovative Medicine Research and Development, said pivotal data for ICOTYDE in psoriatic arthritis are expected later this year, with phase 3 studies in ulcerative colitis and Crohn’s disease underway.
For INLEXZO in bladder cancer, Duato said nearly one in three eligible patients started on an INLEXZO regimen during the second quarter, and new patient insertions grew about 75% from the prior quarter. Taubert said the product is outperforming recent competitive launches in the U.S. and more than doubled sales from the first quarter, though the company is not yet reporting quarterly sales for the product.
MedTech Growth Slows in Cardiovascular MedTech sales were $8.9 billion, up 3.6% operationally, with growth across cardiovascular, surgery and vision. Kurz said cardiovascular grew 3.1%, below recent trends, due mainly to headwinds in electrophysiology and Abiomed.
Electrophysiology grew 3.1%, supported by procedure growth, commercial execution and new products, but partially offset by competitive pressure in pulsed field ablation and an estimated 400-basis-point negative impact from China inventory. Duato said VARIPULSE, the company’s pulsed field ablation platform for atrial fibrillation, has treated more than 85,000 patients worldwide.
Abiomed declined 2% as U.S. procedure pressures weighed on heart recovery. Tim Schmid, Executive Vice President and Worldwide Chairman, MedTech, said in the Q&A that the slowdown followed a neutral clinical trial in the U.K. focused on high-risk PCI, which led physicians to become more selective. Schmid characterized the issue as behavioral rather than structural and said the company is engaging with physicians while awaiting PROTECT IV data expected in 2027.
Surgery grew 2.3%, vision grew 5.6% and orthopedics grew 4.2%. Schmid said three of the four MedTech businesses — surgery, vision and orthopedics — accelerated in the quarter and performed above expectations. He also said the company is not seeing evidence of a broad-based slowdown in procedure volumes across its portfolio.
Guidance Raised for 2026 Chief Financial Officer Joe Wolk said Johnson & Johnson ended the quarter with about $21 billion in cash and marketable securities and about $49 billion of debt, resulting in a net debt position of about $28 billion. Year-to-date free cash flow totaled approximately $8.7 billion, and Wolk said the company remains on track for full-year free cash flow approaching $21 billion.
Wolk raised full-year operational sales growth guidance by $400 million, now expecting growth of 6.5% to 7.1%, with a midpoint of $100.6 billion. Including currency, reported sales growth is expected to be 7.0% to 7.6%, with a midpoint of $101.1 billion. The company’s 2026 calendar includes a 53rd week, which Wolk said provides an approximately 100-basis-point benefit.
Adjusted operational EPS is now expected to range from $11.50 to $11.65, an $0.18 increase at the midpoint. Reported EPS is projected at $11.60 to $11.75. Wolk said the updated outlook reflects second-quarter performance, uptake of new launches, operating efficiencies and anticipated reduction and recoupment of certain tariff-related costs.
Wolk also said the company’s outlook does not include the impact of pending acquisitions such as Firefly Bio, which Johnson & Johnson expects to close in the third quarter. Duato said the planned acquisition would add another antibody platform and strengthen the company’s next-generation oncology pipeline.
Pipeline and Portfolio Updates Management pointed to several second-half catalysts, including potential FDA approval of IMAAVY for warm autoimmune hemolytic anemia and data readouts for TECVAYLI with TALVEY, pasritamig, J&J 6143, INLEXZO, ICOTYDE and CAPLYTA. In MedTech, expected catalysts include launches tied to electrophysiology, Shockwave catheters, the OTTAVA robotic surgical system, ETHICON 4000 and vision products.
Wolk said the company continues to evaluate separation options for DePuy Synthes and remains on track for a mid-2027 separation. Duato closed the call by saying Johnson & Johnson’s growth momentum is expected to carry into the second half of 2026 and 2027, with the company maintaining its ambition for double-digit growth by the end of the decade.
About Johnson & Johnson NYSE: JNJJohnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Johnson & Johnson Right Now?Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
For the quarter ended June 2026, Johnson & Johnson (JNJ - Free Report) reported revenue of $25.31 billion, up 6.6% over the same period last year. EPS came in at $2.90, compared to $2.77 in the year-ago quarter.
The reported revenue represents a surprise of +0.53% over the Zacks Consensus Estimate of $25.18 billion. With the consensus EPS estimate being $2.84, the EPS surprise was +2.11%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Johnson & Johnson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Organic Sales Growth (Operational growth): 5.6% compared to the 6.3% average estimate based on three analysts.Sales- Innovative Medicine- Oncology- CARVYKTI- WW: $657 million compared to the $640.24 million average estimate based on three analysts. The reported number represents a change of +49.7% year over year.Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW: $584 million versus the three-analyst average estimate of $575.14 million. The reported number represents a year-over-year change of +41.1%.Sales- International: $10.78 billion compared to the $10.75 billion average estimate based on three analysts. The reported number represents a change of +5.7% year over year.Sales- MedTech- Cardiovascular- Electrophysiology- WW: $1.53 billion compared to the $1.58 billion average estimate based on three analysts. The reported number represents a change of +4.4% year over year.Sales- MedTech- Total: $8.93 billion compared to the $8.96 billion average estimate based on four analysts. The reported number represents a change of +4.5% year over year.Sales- Innovative Medicine- WW: $16.38 billion versus $16.16 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change.Sales- MedTech- Orthopaedics- Trauma- WW: $827 million versus the three-analyst average estimate of $802.59 million. The reported number represents a year-over-year change of +7.7%.Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW: $740 million compared to the $736.49 million average estimate based on three analysts. The reported number represents a change of +1.8% year over year.Sales- MedTech- Surgery- Advanced- WW: $1.19 billion compared to the $1.19 billion average estimate based on three analysts. The reported number represents a change of +2.2% year over year.Sales- MedTech- Surgery- WW: $2.65 billion versus the three-analyst average estimate of $2.61 billion. The reported number represents a year-over-year change of +3.8%.Sales- Innovative Medicine- Cardiovascular / Metabolism / Other- Other- WW: $225 million versus $242.01 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -27.2% change.View all Key Company Metrics for Johnson & Johnson here>>>
Shares of Johnson & Johnson have returned +7.9% over the past month versus the Zacks S&P 500 composite's +1.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition.
The healthcare company posted adjusted earnings per share of $2.90 for the quarter, ahead of the Wall Street consensus estimate of $2.85.
Revenue rose 6.6% year over year to $25.31 billion, exceeding analysts' expectations of $25.05 billion.
Net earnings were $5.53 billion, or $2.27 per diluted share, compared with $5.54 billion, or $2.29 per share, a year earlier. Adjusted net earnings increased 5.7% to $7.08 billion.
The Innovative Medicine segment remained the primary growth driver, with sales rising 7.8% to $16.38 billion, above expectations of approximately $16.1 billion. MedTech sales increased 4.5% to $8.93 billion.
Among individual products, immunology drug Tremfya generated $2 billion in sales, up 72.5% from a year earlier and above analyst estimates of $1.74 billion. Cancer therapy Darzalex also contributed to growth, helping offset the impact of patent expirations affecting older medicines such as Stelara.
Following the stronger-than-expected quarter, Johnson & Johnson (NYSE:JNJ) increased its full-year 2026 guidance. The company now expects reported sales of $100.8 billion to $101.4 billion, with a midpoint of $101.1 billion, and adjusted earnings per share of $11.60 to $11.75, compared with its previous outlook. The updated adjusted EPS guidance has a midpoint of $11.68.
Johnson & Johnson (NYSE:JNJ) also reported year-to-date free cash flow of approximately $8.7 billion, up from $6.21 billion in the prior-year period.
Joaquin Duato, Johnson & Johnson’s CEO, highlighted the company's innovation pipeline, noting recent approvals for Tremfya in active psoriatic arthritis, Caplyta for preventing relapse in schizophrenia, and the Dual Energy ThermoCool SmartTouch SF platform, alongside positive clinical data for several oncology and surgical programs.
“With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history,” Duato said.
Shares of Johnson & Johnson were little changed at $253 following the release of its earnings.
Johnson & Johnson delivered strong Q2 2026 results, with 6.6% annual revenue growth and robust performance across Pharma and MedTech divisions. JNJ maintains mid-to-high single digit revenue growth, a portfolio of 15+ "blockbuster" drugs, and a solid pipeline, supporting its blue-chip status. I am downgrading JNJ from Strong Buy to Buy due to valuation normalization and tempered forward share price expectations, despite continued operational strength.
Key Takeaways J&J beat Q2 earnings and sales estimates and raised its 2026 sales and adjusted EPS outlook.JNJ's Innovative Medicine growth was led by Darzalex, Tremfya and newer drugs despite Stelara LOEJ&J's MedTech sales rose year over year but slightly missed estimates despite broad-based growth. Johnson & Johnson’s (JNJ - Free Report) second-quarter 2026 earnings came in at $2.90 per share, which beat the Zacks Consensus Estimate of $2.84. Earnings rose 4.7% from the year-ago period.
Adjusted earnings exclude intangible amortization expense and special items. Including these items, reported earnings were $2.27 per share, down 0.9% year over year.
Sales of this drug and medical devices giant came in at $25.3 billion, which marginally beat the Zacks Consensus Estimate of $25.2 billion.
Sales rose 6.6% from the year-ago quarter, reflecting an operational increase of 5.6% and a positive currency impact of 1.0%. Organically, excluding the impact of acquisitions/divestitures and currency, sales rose 5.7% on an operational basis.
Second-quarter sales in the domestic market rose 7.3% to $14.53 billion. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, domestic sales rose 7.4% in the quarter.
International sales rose 5.7% on a reported basis to $10.8 billion, reflecting an operational increase of 3.4% and a positive currency impact of 2.3%. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, international sales rose 3.5% in the quarter.
JNJ’s Innovative Medicine Sales Maintain MomentumInnovative Medicine sales rose 7.8% year over year to $16.38 billion. Operational sales increased 6.8%, while adjusted operational growth was 6.9%. U.S. sales advanced 8.9%, and international sales increased 6% on a reported basis. Innovative Medicines sales slightly beat the Zacks Consensus Estimate of $16.16 billion.
Higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment’s growth. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. These gains were partly offset by lower sales of Stelara, Remicade, Imbruvica and Zytiga.
Sales of blockbuster multiple myeloma medicine Darzalex rose 18.9% to $4.21 billion in the quarter. Sales beat the Zacks Consensus Estimate of $4.16 billion.
Imbruvica sales declined 18.6% to $599 million. Rising competitive pressure in the United States due to new oral competition has been hurting Imbruvica's sales for the past few quarters. Imbruvica sales missed the Zacks Consensus Estimate of $630.0 million.
Erleada sales increased 9.5% to $995 million. Erleada sales missed the Zacks Consensus Estimate of $1.06 billion.
Among the newer cancer drugs, Carvykti sales surged 49.4% to $657 million, while Tecvayli sales jumped 56.5% to $260 million.
Talvey sales advanced 63.3% to $174 million. Rybrevant/Lazcluze sales climbed 60.8% to $289 million.
JNJ’s Tremfya and Neuroscience Drugs Offset StelaraWorldwide immunology sales declined 3.7% to $3.84 billion as biosimilar competition continued to put pressure on Stelara, whose sales fell 55.2% to $740 million. However, Stelara sales beat the Zacks Consensus Estimate of $654.0 million.
Several biosimilar versions of J&J’s multi-billion-dollar immunology drug, Stelara, were launched in the United States in 2025. According to patent settlements and license agreements, Amgen (AMGN - Free Report) , Teva Pharmaceutical Industries (TEVA - Free Report) , Samsung Bioepis/Sandoz, and some other companies have launched Stelara biosimilars.
Tremfya remained the key growth driver, with sales rising 72.5% to $2.05 billion. Tremfya sales beat the Zacks Consensus Estimate of $1.85 billion.
Remicade revenues decreased 25.8% to $338 million. Simponi and Simponi Aria sales declined 10.5% to $618 million.
Neuroscience sales increased 14% to $2.34 billion. Spravato revenues grew 40.8% to $584 million.
Caplyta, added from last year’s acquisition of Intra-Cellular Therapies, generated $361 million, up 70.9% year over year.
Invega Sustenna/Xeplion/Invega Trinza/Trevicta sales rose 2.3% to $1.02 billion in the quarter.
JNJ’s PAH and Other Drugs’ PerformancePulmonary hypertension drug Uptravi recorded second-quarter 2026 sales of $494 million, up 3.8% year over year. Opsumit/Opsynvi sales increased 3.4% to $602 million.
Xarelto sales rose 7.1% to $664 million. Sales of Prezista/Prezcobix/Rezolsta/Symtuza declined 6.3% to $372 million.
J&J’s MedTech Business Posts Broad-Based GainsMedTech sales increased 4.5% to $8.93 billion, including operational growth of 3.6%. However, MedTech segment sales slightly missed the Zacks Consensus Estimate of $8.96 billion.
Excluding the impact of all acquisitions and divestitures, and currency, on an adjusted operational basis, worldwide sales rose 3.7%.
The MedTech business has improved in the past few quarters, driven by strong performance in three focus areas: Cardiovascular, Surgery and Vision.
Cardiovascular sales rose 4% to $2.40 billion. Shockwave revenues advanced 14.6% to $335 million, while electrophysiology sales increased 4.4% to $1.53 billion.
Surgery sales grew 3.9% to $2.65 billion, supported by wound-closure and biosurgery products. Vision revenues increased 6% to $1.45 billion, led by contact lenses. Orthopaedics sales rose 4.9% to $2.42 billion, with trauma revenues increasing 7.6%.
JNJ Slightly Ups 2026 GuidanceJ&J raised its 2026 reported sales guidance to $100.8-$101.4 billion from $100.3-$101.3 billion. The sales projection indicates growth in the range of 7.0%-7.6% versus the prior expectation of 6.5%-7.5%. Operational sales growth is expected in the range of 6.5%-7.1% versus the prior expectation of 5.9%-6.9%.
Adjusted operational sales (excluding currency impact, acquisitions/divestitures) growth is expected in the range of 6.2%-6.8% versus the prior expectation of 5.6%-6.6%.
Adjusted earnings per share guidance was raised from a range of $11.45-$11.65 to $11.60- $11.75 per share. Adjusted earnings per share growth is expected in the range of 7.5%-8.9% versus the prior expectation of 6.1%-8.1%.
Our Take on JNJ’s Q2 ResultsJohnson & Johnson delivered a solid second-quarter performance, with adjusted earnings and sales topping expectations. Sales of key therapies — Darzalex and Tremfya — surpassed expectations, while Erleada fell short. Stelara sales were also better than expected. MedTech segment sales came in slightly below expectations.
Stelara’s loss of exclusivity (LOE) negatively impacted the Innovative Medicines segment’s growth by 760 basis points in the quarter. Despite Stelara's LOE, the Innovative Medicines unit once again outperformed estimates, driven primarily by strong momentum in oncology. Newer therapies and recent launches made a meaningful contribution to overall sales growth, helping offset biosimilar pressure. Encouraged by the quarter’s performance, J&J raised its 2026 financial guidance for the second time this year.
However, despite the beat and raise quarter, J&J’s shares declined more than 2% in pre-market trading on Tuesday, probably due to the MedTech miss and only a modest beat on overall sales.
J&J’s shares have risen 24% year to date compared with 12.1% appreciation of the industry.
Image Source: Zacks Investment Research
Nonetheless, J&J expects 2026 to be a year of accelerated growth. The company expects both its Innovative Medicines and MedTech segments to deliver stronger growth this year. The company is confident that it can achieve its target of generating more than $100 billion in revenues in 2026. Earlier, it had said that it expects sales to continue to improve in 2027, with a “line of sight” to double-digit growth by the end of the decade. An update is expected on the conference call.
J&J’s Zacks Rank & Stock to ConsiderJ&J currently has a Zacks Rank #3 (Hold).
A better-ranked drugmaker is Exelixis (EXEL - Free Report) , which has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exelixis’s shares have risen 27.2% so far this year. Estimates for its 2026 earnings per share have increased from $3.49 to $3.54 over the past 60 days.
Exelixis’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.04%.
